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PREFACE 
 
 
 
 
 
 This dissertation was conducted under the supervision of Prof. Dr. Masami 
ISHIBASHI of the Natural Products Chemistry Laboratory. The main theme of the 
research project is on the discovery of potent Wnt signal inhibitors from natural resources.  
Some of the plants used in the isolation were identified as potent source of compounds 
with biological activity based on the screening study conducted by the past members of 
the laboratory. Moreover, the assay systems used in this research followed the established 
or constructed assay system of the laboratory. Chapters 3-6 present most of the works on 
the Wnt signal inhibition including activity assay, isolation and structural elucidation of 
the potent compounds, and plausible mechanism. A version of Chapter 3 has been 
published [Fuentes, R. G.; Toume, K.; Arai, M. A.; Koyano, T.; Kowithayakorn, T.; 
Ishibashi, M. Heterocycles 2014, 88, 1501-1509]. In Chapter 7, the possible role of one 
Wnt inhibitor, scopadulciol, in overcoming TRAIL resistance is discussed. Chapters 9-12 
present the work on the induction of Ngn2 promoter activity using an assay system 
constructed by the laboratory. This research project was conducted in the early part of my 
PhD work.  
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ABSTRACT 
 
 
 
 The Wnt signal plays a crucial role in many biological processes. Deregulation of 
the pathway has been implicated in the occurence of human diseases particularly in 
cancer and tumorigenesis. As we continue our efforts to search for Wnt signal inhibitors, 
we have identified three plant extracts KKP261 Curcuma comosa, KB302 Azadirachta 
excelsa and KKB304 Scoparia dulcis to possess Wnt signal inhibitory activity. Activity-
guided multi-step separation of the extracts led to the isolation of ten compounds (1-10) 
from C. comosa, four (11-14) from S. dulcis and eight (15-22) from A. excelsa. 
Compounds 1, 2 and 15 are new compounds. Six compounds (1, 8, 17-20) were identified 
potent Wnt inhibitors using the STF/293 reporter (TOP) assay. Compound 18 showed 
cytotoxic activity against AGS and HCT116 cancer cell line. It did not affect the level and 
localization of β-catenin, but downregulated the c-myc level. Compound 11, though was 
not identified as a positive compound using STF/293, it showed cytotoxicity against AGS 
which has an active Wnt signal. It exhibited Wnt inhibition in AGS by p53- and 
proteasome-mediated β-catenin degradation and inhibition of nuclear β-catenin 
accumulation. Furthermore, 11 sensitizes AGS to TRAIL-induced apoptosis. 
 
 
 
 
 
 
 
1 
 
CHAPTER 1 
 
 
 
Introduction 
  
 
 
1.1. Background of the study 
In the last 30 years, natural products are still considered as important sources of 
leads for the development of drugs for the treatment of human diseases.
1
 One of the 
natural resources utilized since the ancient times are the plants. Since the early 
civilizations, as we all know, plants were already used for medicinal purposes. It is 
reported that there is approximately 300,000 species of higher plants, and this figure tells 
that the plant kingdom offers huge areas for exploration of compounds with 
pharmaceutical application.
2
   
With the advent of new technologies and research techniques, scientists are able to 
fully understand the biochemistry of many human diseases. One of these important 
discoveries is the Wnt signal pathway. From its discovery in the 1980s, important 
findings had been reported on its association with human diseases particularly cancer.
3
 
Even though there are several advances and developments to cure cancer, to win the fight 
against cancer remains a challenge. According to the GLOBOCAN Project of the 
International Agency for Research on Cancer (IARC), cancer is one of the leading causes 
of death in the world.
4
 From the same report, the top five most frequent cancers are lung, 
breast, colorectal, prostate and stomach cancers. In Japan, stomach, colon and rectum are 
among the leading cancer sites among Japanese in 2008.
5
 About 70-80% of colorectal 
cancer has an active Wnt signal. Thus, targeting the Wnt pathway provides a promising 
therapeutic strategy for the management of these diseases.  
2 
 
With the vast compounds available from natural resources such as plants, they are 
considered as potential sources of Wnt inhibitors. Several compounds had been reported 
to affect the Wnt signal and showed cytotoxicity against some colorectal cancer, and 
possibly, could be leads for drug development.
6
 Though our laboratory has already 
reported some Wnt inhibitors derived from plants, it is still significant to continue 
exploring other compounds that could be potent Wnt inhibitors.  
 
1.2 The Wnt Signalling Pathway 
The Wnt/β-catenin pathway is a conserved signalling cascade that regulates the 
cellular development and fate determination.
7
 In the absence of the Wnt protein, β-
catenin binds to the destruction complex which is composed of axin, adenomatous 
polyposis coli (APC), glycogen synthase kinase-3β (GSK3β), and casein kinase-1α 
(CKIα) (Figure 1.1). In the destruction complex, β-catenin is sequentially phosphorylated 
by CKIα and GSK-3β.8 CKIα primes the β-catenin by phosphorylating it at S45, then 
GSK-3β phosphorylates at S33, S37 and T41. β-Transducin repeat-containing protein (β-
TrCP) recognizes the phosphorylated β-catenin, and facilitates the ubiquitination process 
which is then rapidly degraded by the proteasome.
9
 Removal of β-catenin from the 
destruction complex is accomplished by the direct proteasomal degradation. In the 
presence of the Wnt protein, the Wnt protein binds to frizzled and low-density-
lipoprotein related protein (LRP5/6). The destruction complex translocate to the 
membrane, and axin associates with the phosphorylated LRP.
10
 Inactivation of the 
destruction complex is said to be accomplished by the following mechanisms: 
 
a. Upon Wnt-receptor ligand interaction, binding of the destruction complex results 
in the dissociation of β-TrCP.11 Without the β-TrCP, phosphorylated β-catenin is 
3 
 
no longer ubiquitinated and degraded. The destruction complex is inactivated due 
to saturation of phosphorylated β-catenin which makes GSK3β inactive by 
feedback inhibition. This also results to the inability of newly synthesized β-
catenin to bind in the destruction complex. 
b. Another mechanism also showed that in the presence of the Wnt protein, 
dishevelled (Dsh), by an unknown mechanism, is hyperphosphorylated which then 
inhibits the GSK3β activity.  
Wnt OFF        Wnt ON 
 
 
 
Figure 1.1. The Wnt/β-catenin Pathway. LRP: lipoprotein receptor-related protein; β-
cat: β-catenin; Dsh: deshevelled; GSK3β: glycogen synthase kinase 3β; 
CK1α: casein kinase 1α; APC: adenomatous polyposis coli; β-TrCP: β-
transducin repeat containing protein; TLE: transducin-like enhancer of 
split; TCF: T-cell factor  
 
When the destruction complex is inactivated, cytosolic β-catenin accumulates and 
increases its stability which will lead to its nuclear translocation. Then, β-catenin 
complexes with and activates T-cell factor/lymphoid enhancing factor (TCF/LEF) for the 
transcription of target genes such as c-myc, cyclin D1, and survivin.
12,
 
13,
 
14
 
4 
 
1.2.1. Alternative pathway for the degradation of β-catenin 
 β-Catenin is also reported to be degraded independent of GSK3β phosphorylation 
and β-TrCP. It was found that β-catenin can be degraded by the action of Siah-1 which 
has been shown to induce cell cycle arrest, tumor suppression, and apoptosis. Siah-1 
expression is reported to be p53-inducible in response to DNA damage.
15,16
  In this 
mechanism, Siah-1 makes a complex with SIP (Siah interacting protein) and Skp1 (S-
phase kinase associated protein 1), and interacts with APC. Ebi binds β-catenin and 
recruits it to the Siah-1-SIP-Skp1 complex for polyubiquitination and proteasomal 
degradation (Figure 1.2).
16
  
 
 
 
 
 
 
 
 
 
Figure 1.2. β-Catenin regulation via the Siah mechanism. Siah-1: seven in 
absentia homolog 1; SIP: Siah interacting protein; Skp1: S-phase kinase-
associated protein 1. 
5 
 
1.3. Wnt Signal and Diseases 
 Aberrant activation of the Wnt signal pathway is implicated in the development of 
various diseases and abnormalities. Most cancer cells, particularly colon and melanoma 
cancer cells, harbor mutations which upregulate the Wnt signaling pathway.
6, 7
 In fact, 
about 70-80% of the colorectal cancer cells have an active Wnt signal.
17
 These cells 
contain mutations in APC, axin or in β-catenin itself which leads to β-catenin stabilization 
and upregulation of the TCF-transcription activity. Furthermore, deregulated activation of 
the Wnt pathway is not restricted only to cancer development. It has also been linked to 
the incidence of type II diabetes, and contributes to abnormalities including high bone 
mass and oligodontia.
18
  Table 1.1 shows some diseases associated with the aberrant 
activation of the Wnt pathway. 
 
Table 1.1 List of diseases associated with aberrant activation of the Wnt signal.
18
 
Wnt pathway abnormalities Disease 
Increased expression of the Wnt ligands Colon cancer, breast cancer, melanoma, 
gastric cancer, Barrett’s esophagus, 
rheumatoid arthritis, schizophrenia 
Mutations or reduced expression in APC 
(decrease of activity) 
Colon cancer, Barrett’s esophagus 
Mutations in β-catenin (increase in activity) Colon cancer, gastric cancer, hepatocellular 
cancer 
Mutation in Axin (decrease in activity) Colon cancer, oligodontia 
Increase in activity of LRP5 High bone density 
Increased expression of TCF4 Type II diabetes 
 
Most of the gastrointestinal cancer cells have an active Wnt signal because they harbour 
mutations in either APC or β-catenin.19 Table 1.2 shows the different mutations found in 
some gastrointestinal cancer cells. These mutations lead to the accumulation of the β-
catenin in the cytoplasm due to the inability of the destruction complex to phosphorylate 
β-catenin, or impairment of the β-TrCP/ubiquitin-mediated degradation.20 
6 
 
     Table 1.2. Some gastrointestinal cancer cells with active Wnt signalling pathway.
19, 20
 
Cancer cell Line Mutation  
Colon cancer   
SW480  APC truncation 
C-terminus residue 1338 
 Wild type β-catenin 
β-Catenin phosphorylation 
present but degradation is 
slow. 
DLD1  APC truncation 
 C-terminus residue 1427 
 Wild type β-catenin 
β-Catenin phosphorylation 
present but degradation is 
slow. 
HCT116  Wild type APC 
 One allele wild-type β-catenin 
 One allele mutated β-catenin 
(S45 deletion) 
Lesser S45 phosphorylation 
Gastric   
AGS  Wild type APC 
 β-catenin mutation (G34E) 
Reduce ubiquitin-proteasome 
degradation of β-catenin 
 
 
1.4. Wnt inhibitors and their mechanism of action 
Several natural compounds, as well as synthetic compounds, have been reported 
to inhibit the Wnt signal (Figure 1.3). Quercetin, a flavonoid, exhibits inhibitory activity 
of the Wnt signal in SW480 by decreasing the level of nuclear β-catenin and TCF 
proteins.
21
 Synthetic compounds XAV939 and IWR-1 were shown to increase the 
stability of axin. XAV939 was reported to inhibit the activity of tankyrase which 
promotes ubiquitination of axin.
22
 Pyrvinium pamoate was first reported to inhibit the 
Wnt signal through the activation of CK1α.23 However, a recent study had presented 
another probable action mechanism of pyrvinium pamoate.
24
 Their study showed that 
pyrvinium pamoate is not a bona fide activator of CK1α but promotes Akt/PKB 
downregulation and GSK3 activation. Other compounds inhibit the Wnt signal by 
alternative pathways. These alternative mechanisms are important as they involve 
degradation of mutant β-catenin that cannot be phosphorylated by GSK3β. 
Hexachloropene and isoreserpine showed degradation of β-catenin via the Siah-1-
upregulation in HCT116.
25, 26
 Degradation of β-catenin via the Siah-1 mechanism is  
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Figure 1.3. Wnt signal inhibition of some reported compounds via the (a) conventional    
pathway and (b) via an alternative pathway, Siah-1 mechanism. 
 
 
 
 
XAV939 
(IC
50
= 10 nM) 
IWR-1 
(IC
50
= 130 nM) 
Pyrvinium 
(IC
50
= ~10 nM) 
Murrayafoline A 
(IC
50
= ~20 nM) 
Quercetin 
(IC
50
= 27.7 µM) 
Hexachlorophene 
(IC
50
= 7.03 µM) 
Isoreserpine 
(IC
50
= 75 µM) 
Salinomycin 
(IC
50
= 163 nM) 
a 
b 
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independent of GSK3β and β-TrCP. On the other hand, murrayafoline A, a carbazole 
alkaloid derived from Glycosmis stenocarpa, was reported to promote β-catenin 
degradation independent of the phosphorylation and Siah-1 mechanism.
27
 
A number of natural compounds, isolated from either plants or bacteria 
(actinomycetes), have been reported by our group (Figure 1.4). Calotropin, a cardenolide 
from Calotropis gigantea, enhanced the level of CK1α.28 Xylogranin B, a new limonoid 
isolated from Xylocarpus granatum, inhibited the translocation of β-catenin to the 
nucleus.
29
 These two compounds exhibited inhibition of the TCF/β-catenin transcriptional 
activity as well as cytotoxicity activity against colon cancer cells. Moreover, calotropin 
showed to be cytotoxic against the colon cancer cells which are dependent on Wnt 
activity, and not in RKO cancer cells which do not possess active Wnt signal.
28
 
Chromomycin A2
30 
and nonactin
31
 are Wnt inhibitors isolated from actinomycetes.  
 
1.5. Screening of potential Wnt inhibitors: Cell-based luciferase assay system 
 A cell-based luciferase assay using the cell line HEK293 stably transfected with 
TCF reporter gene (SuperTopflash; TOP-TCF optimized binding site: CCTTTGATC) 
was used to determine the TCF/β-catenin transcriptional activity (Figure 1.5). In order to 
stabilize β-catenin in HEK293 cells, they were treated with LiCl to inhibit the activity of 
the GSK3β. The β-catenin translocates to the nucleus, complexes with TCF then binds to 
the TCF binding site of the TCF-luciferase construct, leading to the transcription of the 
luciferase gene. The luciferase activity is evaluated from the luminescence produced from 
the oxidation of the substrate luciferin catalysed by the luciferase protein. Viability assay 
is also conducted as lower luminescence reading can be due to low viability of the 
reporter cells. 
 
Calotropin (IC
50
=1.3 nM) 
(Calotropis gigantea) 
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Xylogranin B (IC
50
 48.9 nM) 
(Xylocarpus granatum) 
2-methoxy-1,4-naphthoquinone  
(IC
50
 48.9 µM) 
(Impatiens balsamina) 
Calotropin (IC
50
 1.3 nM) 
(Calotropis gigantea) 
Isoeletherin (IC
50
 9.5 µM) 
(Eleutherine palmifolia) 
Chromomycin A
2
 
(IC
50
 1.8 nM) 
Nonactin  
(IC
50
 7.2 nM) 
 
Plant-derived Wnt Inhibitors 
 
 
 
 
 
 
 
 
 
 
 
Actinomycete-derived Wnt Inhibitors 
 
 
 
 
 
 
 
 
 Figure 1.4. Wnt inhibitors reported by our group. 
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Figure 1.5. a. Cell-based luciferase assay system using TOP and FOP assays.  
b. Oxidative conversion of luciferin to oxyluciferin catalyzed by the enzyme 
luciferase. 
 
 
a 
b 
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Furthermore, in order to exclude the non-specific effects on luciferase activity, 
transfection with SuperFOPflash (far from optimized TCF-binding site: CCTTTGGCC) is 
also conducted.  FOP plasmid contains a mutant TCF-binding site, and does not respond 
to active Wnt signalling activity. Compounds that inhibit the TOP activity without 
affecting viability of reporter assay cell, and do not significantly affect the FOP activity 
are considered “hits” (Figure 1.6). 
 
1.6. Cytotoxicity assay using FMCA 
 Fluorometric microculture cytotoxicity assay (FMCA) is a simple method to 
determine cytotoxic and/or cytostatic effect in vitro.
32
 In this assay, fluorescein diacetate 
(FDA) is used as the probe. When added to live cells, FDA is hydrolzed by the esterases 
to produce fluorescein, a fluorescent compound (Figure 1.6). 
 
 
 
 
 
Figure 1.6. Enzymatic hydrolysis of fluorescein diacetate to fluorescein. 
 
 
1.7. Aim of the study 
As we continue our efforts to discover other inhibitors, a screening study 
identified three plants KKP261 Curcuma comosa, KKB304 Scoparia dulcis, and 
KKB302 Azadirachta excelsa as potent sources of Wnt inhibitors. In this study, we aim to 
isolate and identify compounds from these identified plants that could be responsible for 
the inhibition of the Wnt pathway. 
12 
 
 Specifically, our objectives are: 
a. To elucidate the structure of the isolated compounds based on their 
spectroscopic data (NMR, mass, UV, IR, and optical rotation) 
b. To determine the TCF/β-catenin transcriptional activity of the isolated 
compound by using the TOP and FOP assay. 
c. To investigate the cytotoxicity of the compounds against a panel of 
gastrointestinal cancer cells. 
d. To identify the putative mode of mechanism on the inhibitory activity by 
Western blot analysis. 
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CHAPTER 2 
 
 
 
Methods 
  
 
 
2.1 General Experimental Procedure 
1
H and 
13
C NMR spectra: JEOL JNM-ECA600, ECP600 and ECP400 spectrometers with 
deuterated solvent 
HRESIMS: JEOL JMS-T100LP spectrometer  
Optical rotation: JASCO P-1020 polarimeter 
UV spectra: Shimadzu UV mini-1240 spectrometer 
CD spectra: JASCO J-720WI spectrophotometer 
IR spectra: ATR in a JASCO FTIR 230 spectrophotometer. 
Microplate reader: Thermo Luminoskan Ascent, Thermo Fluoroskan Ascent 
HPLC: JASCO PU-2080, JASCO RI-2031 Plud (RI Detector), JASCO UV-2075 (UV 
Detector), JASCO OR-2090 (Chiral Detector) 
Flow cytometer: Guava EasyCyte5 
 
2.2. Cell culture 
The STF/293 cell line was a generous gift from Prof. Jeremy Nathans (John 
Hopkins Medical School); HEK293, HCT116, DLD1, and RKO cells were purchased 
from ATCC; SW480 cells were derived from the Institute of Development, Aging, and 
Cancer, Tohoku University. STF/293, HEK293, SW480, DLD1, and HCT116 were 
cultured in Dulbecco’s modified Eagle medium (DMEM) with 10% FBS. Cultures were 
maintained in a humidified incubator at 37 
o
C in 5% CO2/95% air.  
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2.3. Reporter gene assay and transfection 
The TCF/β-catenin transcriptional activity was determined using the method 
previously described.
1
 STF/293 cells which were stably transfected with SuperTOPflash, 
were seeded into 96-well plates (3 x 10
4 
cells/well),  and after 24 h incubation, treated 
with compounds combined with 15 mM LiCl. After 24 h, cells were lysed and luciferase 
activity was measured Luciferase Assay System (Promega). Quercetin which was 
previously shown to possess β-catenin/TCF transcriptional inhibitory activity was used as 
a positive control.
2
 For the negative reporter assay, HEK293 cells were briefly split into 
24-well plates (1 x 10
5 
cells/well). After 24 h, cells were transfected with 500 ng/well of 
the luciferase reporter construct (SuperFOPflash) and 50 ng/well of pRL-CMV (Promega, 
USA) for normalization. At 12 h post-transfection, the compounds combined with 15 mM 
LiCl were added.  Cells were lysed after 24 h incubation, and luciferase activity was 
measured using the the PICAGENE Dual Seapansy (Toyo Ink). SuperFOPflash plasmid 
was generously given by Prof. Randall T. Moon of the University of Washington. 
 For the TCF/β-catenin transcriptional activity in AGS cells, 1 x 105 cells/well 
were seeded into each well of 24-well plate, and incubated for 24 h. Then, the cells were 
transfected with either SuperTOPflash or SuperFOPflash (500 ng/well) and pRL-CMV 
(25 ng/well). After 24-h post-transfection, the cells were treated with the compound for 
24 h, lysed and the luciferase was measured using the PICAGENE Dual Seapansy (Toyo 
Ink). 
 To determine the relative luciferase activity (%) of each assay, the following 
formulas were used: 
a. Relative TOP Activity using STF/293 reporter cells: 
                     
                               
                       
       
b. Transient transfection for both Relative TOP and FOP Activity 
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 where:  FL = luminescence reading for the Firefly luciferase (TOP or FOP) 
   RL = luminescence reading for the Renilla luciferase (pRL-CMV) 
  
                              
                                     
                                     
       
 
2.4. Cell viability assay. 
Cell viability was measured using the FMCA assay.
3
 STF/293 (3 x 10
4
 cells/well), 
AGS, HCT116, SW480, DLD1, RKO and HEK293 (5 x 10
3
 cells/well) were inoculated 
into 96-well plates for 24 h. Compounds were then added and incubated for another 24 h. 
After incubation, they were treated with fluorescein diacetate (0.35 mg/mL) (Wako) in 
PBS buffer. Fluorescence was detected after 1 h incubation. The percent viability (%) was 
calculated as follows: 
              
                              
                       
      
 
2.5. TRAIL-resistance overcoming activity assay 
The TRAIL-resistance overcoming activity was determined using the method 
described previously.
4
 AGS cells were seeded in 96-well plates (6 x 10
3
 cells/well), 
incubated for 24 h and then, treated with different concentrations of the compounds, 
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either alone or in combination with TRAIL (100 ng/mL). After 24 h, viability was 
assessed using the FMCA method described above. 
 
2.6. Western blot analysis 
Whole cell extracts, cytoplasmic and nuclear fractions were prepared as described 
previously.
5
 The cytoplasmic and nuclear fractions were obtained using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagent (Thermo Scientific) according to 
manufacturer’s recommendations. Proteins were separated by 7.5-12.5% SDS-
polyacrylamide gel and then transferred onto a nitrocellulose transfer membrane (Pall). 
The membranes were blocked with 5% nonfat milk in TBST and probed with anti-β-
catenin (1:2000, BD Biosciences, #610153); anti- GSK3β (1:1000, Santa Cruz 
Biotechnology, #sc-71186), anti- CK1α (1:200, Santa Cruz Biotechnology, #sc-6477), 
anti-phospo-β-catenin (S33/S37/T41) (1:200, Cell Signaling Technology, #9561), anti-
phospo-β-catenin (S45) (1:200, Cell Signaling Technology, #9564), anti-c-myc (1:200, 
Santa Cruz Biotechnology, #sc-40); anti-cyclin D1 (1:1000, Abcam, #ab6152); anti-
survivin (1:500, Cell Signaling Technology, #71G4B7); anti-p53 (1:500, Sigma, #P5813); 
anti-Bcl2 (1:1000, Sigma, #B9804); anti-TNFRSF10A/DR4 (1:500, Sigma, 
#WH0008797M1); anti-DR5 (1:500, Sigma, #D3938); and, anti-β-actin (1:4000, Sigma, 
#A2228) primary antibodies overnight at 4°C. The anti-β-actin antibody served as 
internal control. Then, the membranes were washed with TBST and incubated with either 
horseradish peroxidase conjugated anti-mouse IgG (1:4000, GE Healthcare, NA931VS) 
or anti-rabbit (1:4000, Jackson Immuno Research, 705-035-003) for 1 h at room 
temperature. After washing the membranes with TBST, protein bands were visualized 
using the ECL advance Western detection system (GE Healthcare) or Immobilon Western 
chemiluminescent HRP substrate (Millipore). 
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2.7. Cell cycle analysis by flow cytometry 
The distribution of cells, with treatment or without treatment, in the different 
phases of the cell cycle was estimated by measuring the cellular DNA using flow 
cytometry.
6
 Random population of cells was seeded in 12-well plate (1 x 10
5
 cells/well)  
for 24 h and treated as described. The attached cells were washed with PBS and then 
detached with trypsin. All the washings and the medium were combined, centrifuged at 
1000 rpm for 5 min, and the cells were then washed 2x with PBS. After washing, the cells 
were resuspended in 0.3 mL PBS and fixed in 70% ethanol overnight (>18 h) at 20
°
C. 
After fixation, the cells were washed with PBS, centrifuged and resuspended in 0.25 mL 
PBS. It was then added with 5 µL RNAse (10 mg/mL, Sigma) and incubated for 1 h at 
37 °C. Then, 10 µL PI (10 mg/mL, Sigma) was added and incubated for 15 min in the 
dark. Stained cells were run in Guava Easycyte5 (Millipore) and analysed using Guava 
InCyte software (Millipore). 
 
2.8. Apoptosis study by flow cytometric analysis 
Cells were seeded in 12-well plate (1 x 10
5 
cells/well) for 24 h, and treated as 
described. After the incubation period, both the floating and attached cells were collected. 
The cells were harvested and washed using the same process as described in the cell cycle 
analysis.  The cells were then stained with propidium iodide (PI) and Annexin-V-fluos 
staining kit (Roche) according to the manufacturer’s protocol and run in Millipore Guava 
Easycyte5. Data were analysed using Guava InCyte software (Millipore).  
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CHAPTER 3 
 
 
 
Diarylheptanoids from Curcuma comosa with  
Wnt/β-catenin signal inhibitory activity 
 
 
 
3.1. Plant description 
C. comosa belongs to the Zingiberaceae family. It is distributed in Thailand, 
Indonesia and Malaysia. The rhizome has been used by local folks as an anti-
inflammatory agent. Previous chemical studies showed that the rhizome of this plant 
contained diarylheptanoids and sesquiterpenes.
1, 2
 The diarylheptanoids of this plant had 
been reported to have estrogenic
3
 and anti-inflammatory activities.
4
 The plant sample 
(rhizome) used in this study was collected from Thailand and, a reference specimen 
(KKP261) has been deposited in the laboratory. During the screening, the MeOH of C. 
comosa showed a decrease in TOP activity by 82% at 50 μg/mL (Figure 3.1). The 
viability of STF/293 reporter cells at the same concentration was 84%. 
 
 
 
 
 
 
 
 
Figure 3.1. Bar graphs showing the dose-dependent TOP activity of KKP261 
MeOH extract. The line graph represents cell viability. All data are 
presented as the mean ± s.d. (n=3). 
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3.2. Isolation of the constituents 
Figure 3.2 shows the isolation scheme of C. comosa. The dried rhizome of C. 
comosa (226 g) was extracted using MeOH. The MeOH crude extract (6.6 g) of C. 
comosa was directly subjected to silica gel column chromatography (φ50 x 270 mm) 
eluting with the hexane-EtOAc gradient system (1:0 to 0:1) to give fractions 1A-1L. 
Fraction 1E (76.5 mg) eluted with hexane:EtOAc (8:2) was recrystallized to give 
compound 9 (28.4 mg). Fraction 1J (548 mg), which showed high activity on the TOP 
assay, was then subjected to ODS flash column chromatography (φ25 x 180 mm) to yield 
fractions 3A-3H. Active fraction 3D (59 mg) eluted with MeOH:H2O (1:1) was further 
purified using silica gel column chromatography (φ25 x 170 mm; CHCl3:MeOH gradient 
system (1:0 - 0:1)) to give compound 4 (11.2 mg). Another fraction from 3D was further 
purified by preparative HPLC [Cosmosil 5C18-AR-II; φ10 x 250 mm; 60% MeOH] to 
give compounds 1 (5.7 mg) and 5 (4.9 mg). Fraction 3B (58.2 mg) was subjected to flash 
silica column chromatography (φ25 x 230 mm) using CHCl3: MeOH (1:0 to 0:1) to give 
fractions 6A-6H. Fraction 6B was identified as compound 10 (6.2 mg). Fraction 6F was 
further purified by preparative HPLC [Cosmosil 5C18-AR-II; φ10 x 250 mm; 53% 
MeOH] to afford compound 6 (2.9 mg). Fraction 6C gave compound 3 (1.1 mg) after 
purification by HPLC [Cosmosil 5C18-AR-II; φ10 x 250 mm; 45% MeOH]. The active 
fraction 1K was subjected to ODS flash column chromatography (φ45 x 180 mm) and 
eluted with increasing MeOH (67-100%), followed by silica gel column chromatography 
(φ30 x 235 mm) using CHCl3:MeOH (1:0 to 0:1) yielded ten fractions (11A-11J). 
Fraction 11H was identified as compound 7 (14.8 mg). Fraction 11E, which showed weak 
activity, was further purified using by preparative HPLC [Cosmosil π-NAP; φ10 x 250 
mm; 60% MeOH] to give a mixture (6.8 mg) of compound 2 and an unknown compound.  
25 
 
 
 
 
Figure 3.2. Isolation chart of C. comosa. 
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Another active fraction, 1I (203.2 mg), was subjected to ODS flash column 
chromatography (φ40 x 170 mm) and eluted with increasing MeOH (60%-80%) to give 
11 fractions (15A-15K). Fraction 15F (18.3 mg), which showed strong activity, was 
subjected to silica gel column chromatography using CHCl3:MeOH (10:1-0:1) and 
yielded 8 fractions (16A-16H).  Fraction 16D (7.1 mg) was further purified using 
Sephadex LH-20, followed by silica gel column chromatography [φ25 x 150 mm; 
CHCl3:MeOH (1:0-0:1)] to afford compound 8 (0.7 mg). 
 
 
3.3. Characterization of the isolated compounds 
Compound 1, isolated as a colorless solid, gave a molecular formula of C21H26O5 
with HRESIMS at m/z 381.1634 ([M+Na]
+
, C21H26O5Na, Δ -4.4 mmu. The 
1
H and 
13
C 
NMR data (Table 3.1) of 1 are similar to the NMR spectra its reported enantiomer (ent-
1).
5
 Compound 1 gave a negative optical rotation, which suggests a 3S,5S configuration, 
while its reported 3R,5R enantiomer (ent-1) had a positive value. To further confirm the 
configuration of 1, we conducted deacetylation to produce hannokinol (7). The identity of 
the deacetylated product was verified by comparison of its NMR spectra with the isolated 
compound 7.
6, 7
 Optical rotation of the deacetylated product was determined using 
reversed phase HPLC equipped with an optical rotation detector (ORD) and its response 
was compared with the isolated (-)-hannokinol (7). The 3R,5R form (ent-7) was 
previously reported to be [α]26D +4.0 (c 0.10 MeOH),
7
 while the 3S,5S form (7) was found 
to be [α]25D -19.0.
6
 Compound 7 and the deacetylated product of 1 both gave a negative 
response in the ORD. These findings suggest that the deacetylated product of 1 had a 
negative optical rotation. Therefore, the structure of compound 1 was determined to be (-
)-(3S,5S)-3-acetoxy-5-hydroxy-1,7-bis(4-hydroxyphenyl)heptane. 
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Table 3.1. 
 1
H (600 MHz) and 
13
C (150 MHz) spectral data for compounds 1 and 2. 
a
 measured in CD3OD 
                      b
 measured in CDCl3 
 
 
 
 
 
 
Position 
 1
a 
  2
b 
 1H (δ, ppm; J, Hz) 13C (δ, ppm)   1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1  2.48 (2H, m) 32.0   2.56 (2H, m) 30.7 
2  1.87 (2H, m) 38.0   1.74 (2H, m) 40.0 
3  5.06 (1H, m) 73.0   3.85 (1H, m) 72.4 
4  1.72 (1H, m) 
1.60 (1H, m) 
43.0   1.56 (2H, m) 
 
42.8 
5  3.51 (1H, m) 68.1   3.85 (1H, m) 72.5 
6  1.63 (2H, m) 41.0   1.74 (2H, m) 39.9 
7  2.63 (1H, m) 
2.54 (1H, m) 
31.8   2.66 (2H, m) 
 
31.9 
1’   133.7    132.9 
2’  6.96 (1H, d, 8.7) 130.3   6.39 (1H, s) 104.9 
3’  6.67 (1H, d, 8.7) 116.1    146.9 
4’   156.4    132.8 
5’  6.67 (1H, d, 8.7) 116.1    146.9 
6’  6.96 (1H, d, 8.7) 130.3   6.39 (1H, s) 104.9 
1”   134.2    133.3 
2”  6.98 (1H, d, 8.7) 130.3   6.99 (1H, d, 8.3) 129.4 
3”  6.68 (1H, d, 8.7) 116.1   6.73 (1H, d, 8.3) 115.3 
4”   156.4    154.2 
5”  6.68 (1H, d, 8.7) 116.1   6.73 (1H, d, 8.3) 115.2 
6”  6.98 (1H, d, 8.7) 130.3   6.99 (1H, d, 8.3) 129.4 
3-OAc  1.98 (3H, s) 21.1 
173.1 
    
3’,5’-OMe      3.82 (6H, s) 56.2 
3,5,4’,4”-OH      4.40 (4H, br s)  
1 
2 1 
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Compound 2 was obtained as a colorless compound. An intense peak at m/z 
399.1762 ([M+Na]
+
, C21H28O6Na Δ -2.1 mmu) was observed in HRESIMS, which is 
consistent with the molecular formula of C21H28O6. A singlet peak at δ 3.82 (6H) was due 
to the two symmetric methoxy groups and were assigned at C-3’ and C-5’. The presence 
of two symmetric benzene protons was indicated by the correlations observed between a 
singlet proton peak at δ 6.39 and carbon peak at δ 104.9 in both HMBC (Figure 3.2) and 
HMQC. They were assigned at H-2’ and H-6’. The two doublets at δ 6.99 (J = 8.3 Hz) 
and 6.73 (J = 8.3 Hz) suggested the presence of 1,4-disubstituted aromatic protons and 
were assigned to four aromatic protons, H-2”/H-6” and H-3”/H-5”, respectively. From 
these results, 2 was assigned as 3,5-dihydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)-7-(4-
hydroxyphenyl)heptane.  
 
 
Figure 3.3. Selected key HMBC of 2 
 
Since compound 2 contains a 1,3-diol goup, we employed the Rychnovsky’s 
method to determine its relative configuration. In the Rychnovsky’s method, syn-isomer 
has carbon resonances for the acetonide methyl groups at 30 and 19 ppm, while the anti-
isomers have methyl resonances in the range of 24-25 ppm.
8
 Acetonidation of 2 produced 
the acetonide 2a which gave an intense peak at m/z 439.2070 ([M+Na]
+
, C24H32O6Na, Δ -
2.7 mmu) based on HRESIMS. The HMQC data of the acetonide 2a showed correlations 
between the two methyl peaks at δ 1.32 and δ 1.62, and 13C peaks at δ 21.9 and δ 32.5, 
29 
 
respectively (Figure 3.3). These results suggested that 2a was produced from a syn-1,3-
diol.
15
 The absolute stereochemistry of 2 remains undefined.  
 
 
 
 
 
 
 
 
 
 
The structures of the five known diarylheptanoids were identified by comparing 
their spectral values and optical rotations with those in the literature.  
 
(5R)-5-hydroxy-7-(4-hydroxyphenyl)-1-(4-hydroxy-3-methoxyphenyl)-3-heptanone 
(3)
5, 9
: 
 
1
H and 
13
C NMR see Table 3.2; ESIMS: m/z 367 [M + Na]
+
 
(3R,5R)-3,5-diacetoxy-1,7-bis(3,4-di- hydroxyphenyl)heptane (4)
10
: 
1
H and 
13
C NMR see Table 3.2; [α]D
25
 +8.3 (c 1.2 EtOH), lit. [α]D
25
 +1.5 (c 1.3 EtOH); 
ESI-MS: m/z 455 [M + Na]
+
 
(3R,5R)-3,5-diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)heptane (5)
5
: 
1
H and 
13
C NMR see Table 3.2; [α]D
26
 +12.2 (c 0.5 MeOH), lit. [α]D
25
 +17.2 (c 0.1 
MeOH); ESI-MS: m/z 439 [M + Na]
+
 
(5S)-5-hydroxy-1,7-bis(4-hydroxyphenyl)heptan-3-one (6)
11, 12  
1
H and 
13
C NMR see Table 3.3; ESI-MS: m/z 337 [M + Na]
+
 
2a 
Figure 3.4. Acetonide derivative (2a) of compound 2 and its HMQC. 
21.9 
32.5 
HMQC of 2a 
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(-)-hannokinol (7)
6
  
1
H and 
13
C NMR see Table 3.3; [α]D
23
 -34.1 (c 0.1 MeOH), lit. [α]D
25
 -19 (not indicated); 
ESI-MS: m/z 339 [M + Na]
+
 
1,7-bis(4-hydroxyphenyl)hepta-4E,6E-dien-3-one (8)
 13 
1
H and 
13
C NMR see Table 3.3; ESI-MS: m/z 293 [M-H]
- 
zederone (9)
14
 
1
H and 
13
C NMR see Table 3.4; [α]D
31
 +240 (c 1.00, CHCl3) lit. [α]D
31
 +290 (c 1.14 
CHCl3); ESI-MS: m/z 515 [2M + Na]
+
 
aerugidiol (10)
15, 16 
1
H and 
13
C NMR see Table 3.4; [α]D
24
 -3.3 (c 1.0, MeOH; lit. [α]D
26
 -17.0 c 1.0 MeOH); 
ESI-MS: m/z 273 [2M + Na]
+
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Table 3.2. 
1
H (600 MHz) and 
13
C (150 MHz) spectral data for compounds 3, 4 and 5. 
Position 
3 4  5 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1 2.74 (2H, m) 30.3 2.44 (2H, t, 8.4) 32.0 2.44 (2H, t, 8.0) 32.0 
2 2.74 (2H, m) 46.4 1.76 (2H, m) 37.7 1.76 (2H, m) 37.8 
3  211.9 4.91  overlapped 71.5 4.85  overlapped 71.5 
4 2.50 (1H, m), 2.58 (1H, m) 51.3 1.83 (2H, m) 39.5 1.83 (2H, m) 39.5 
5 3.99 (1H, m) 68.3 4.91 overlapped 71.5 4.85  overlapped 71.5 
6 1.65 (2H, m) 40.5 1.76 (2H, m) 37.7 1.76 (2H, m) 37.8 
7 2.53 (1H, m), 2.63 (1H, m) 31.9 2.44 (2H, t, 8.4) 32.0 2.50(2H, d, 8.0) 31.7 
1’  134.1  134.3  134.3 
2’ 6.75 (1H, d, 1.8) 113.1 6.59 (1H, d, 1.8) 116.5 6.59 (1H, d, 2.0) 116.5 
3’  149.0  146.1  146.2 
4’  145.8  144.4  144.4 
5’ 6.67 (1H, d, 7.8) 116.1 6.65 (1H, d, 8.4) 116.3 6.68 (1H, d, 8.7) 116.3 
6’ 6.60 (1H, dd, 1.8, 7.8) 121.7 6.47 (1H, dd, 8.4, 1.8) 120.6 6.46 (1H, dd, 8.7, 2.0) 120.6 
1”  134.1  134.3  133.5 
2” 6.98 (1H, d, 7.8) 130.3 6.59 (1H, d, 1.8) 116.5 6.97 (1H, d, 8.4) 130.3 
3” 6.67 (1H, d, 7.8) 116.1  146.1 6.68 (1H, d, 8.7) 116.3 
4”  156.4  144.4  156.5 
5” 6.67 (1H, d, 7.8) 116.1 6.65 (1H, d, 8.4) 116.3 6.68 (1H, d, 8.7) 116.2 
6” 6.98 (1H, d, 7.8) 130.3 6.47 (1H, dd, 8.4, 1.8) 120.6 6.97 (1H, d, 8.4) 130.3 
3-OAc   1.961 (3H, s) 21.1 
172.8 
1.958 (3H, s) 21.1 
172.73 
5-OAc   1.961 (3H, s) 21.1 
172.8 
1.961 (3H, s) 21.1 
172.75 
3’-OCH3 3.80 (3H, s) 56.5     
3 4 5 
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Table 3.3. 
1
H (600 MHz) and 
13
C (150 MHz) spectral data for compounds 6, 7 and 8. 
Position 
6 7 8 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1 2.72 (2H, m) 29.8 2.55 (1H, m) 
2.67 (1H, m) 
2.87 (2H, t, 7.2) 
2 2.72 (2H, m) 46.4 1.68 (2H, m) 2.82 (2H, t, 7.2) 
3  211.9 3.88 (2H, m)  
4 2.52 (1H, m) 
2.59 (1H, m) 
51.3 1.58 (2H, m) 6.23 (1H, d, 16.2) 
5 3.99 (1H, m) 68.3 3.88 (2H, m) 7.38 (1H, dd, 16.2, 10.8) 
6 1.65 (2H, m) 40.5 1.68 (2H, m) 6.82 (1H, dd, 15.6, 10.8) 
7 2.64(1H, m) 
2.72 (1H, m) 
32.0 2.55 (1H, m) 
2.67 (1H, m) 
6.96 (1H, d, 15.6) 
1’  133.3    
2’ 6.98 (1H, d, 8.4) 130.2 6.72 (1H, d, 8.8) 7.02 (1H, d, 9) 
3’ 6.67 (1H, d, 8.8) 116.2 7.02 (1H, d, 8.8) 6.68 (1H, d, 9) 
4’  156.6   
5’ 6.67 (1H, d, 8.8) 116.2 7.02 (1H, d, 8.8) 6.68 (1H, d, 9) 
6’ 6.98 (1H, d, 8.4) 130.2 6.72 (1H, d, 8.8) 7.02 (1H, d, 9) 
1”  134.1   
2” 6.98 (1H, d, 8.4) 130.3 6.72 (1H, d, 8.8) 7.39 (1H, d, 9) 
3” 6.67 (1H, d, 8.8) 116.1 7.02 (1H, d, 8.8) 6.76 (1H, d, 9) 
4”  156.4   
5” 6.67 (1H, d, 8.8) 116.1 7.02 (1H, d, 8.8) 6.76 (1H, d, 9) 
6” 6.98 (1H, d, 8.4) 130.3 6.72 (1H, d, 8.8) 7.39 (1H, d, 9) 
6 7 8 
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Table 3.4. NMR spectroscopic data of compound 9 and 10 (in CDCl3). 
Position 
9 10 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1 5.46 (1H, br d, 9.6) 131.0  87.0 
2α 2.5 (1H, dddd, 3.6, 12, 12.9, 13.2)   24.6  37.7 
2β 2.21 (1H, br d, 12.6)    
3α 2.28 (1H, ddd, 3, 3, 13)   38.0  37.5 
3β 1.26 (1H, ddd, 3, 12.6, 13.2)    
4    64.0  83.7 
5 3.79 (1H, s)   66.5  61.5 
6  192.2 2.63 (1H, d, 14.4) 27.7 
7  122.2  133.3 
8  157.1  n.d. 
9 3.67 (1H, d, 16.2) 
3.73 (1H, d, 16.2) 
  41.9 5.83 (1H, t, 1.8) 128.5 
10  131.0  151.5 
11  123.2  n.d 
12 7.06 (1H, s) 138.0 1.99 (3H, s) 23.2 
13 2.09 (3H, s)   10.3 1.85 (3H, s) 22.5 
14 1.32 (3H, s)   15.7 1.41 (3H, s) 24.6 
15 1.58 (3H, s)   15.1 1.99 (3H, s) 22.4 
 
 
 
 
 
 
 
 
 
 
 
 
10 9 
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3.4. TCF/β-catenin transcriptional inhibitory activity 
Compounds 1, 6, 7, and 8 showed the highest inhibitory activity in the TOP assay 
with IC50 values of 3.0, 1.0, and 2.9 μM, respectively (Figure 3.5). However, only 1 and 8 
did not affect FOP activity up to 5 μM, which suggests that their inhibitory activity was 
specific to the TOP activity. The other diarylheptanoids (2-6) as well as zederone (9) also 
showed dose-dependent inhibitory activity against the TOP assay; however, since their 
IC50 values were higher than 10 μM, they were not subjected to further assays. Aerugidiol 
(10), on the other hand, was inactive. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.5. TOP and FOP activity of compounds 1, 6, 7 and 8. TOP was 
measured using HEK293 cells stably transfected with 
SuperTOPflash reporter gene (STF/293) while the FOP 
activity was measured using HEK293 cells transiently 
transfected with SuperFOPflash reporter gene. Line graph 
represents the viability of STF/293 cells. Data were from 
one experiment representative of at least two independent 
experiments (mean ± s.d). All data are presented as the 
mean ± s.d. (n=3). 
1 8 
6 7 
35 
 
Since the assay involved the addition of LiCl, an inhibitor of glycogen synthase 
kinase-3 (GSK3), the data may suggest that 1 and 8 act downstream of the Wnt signaling 
pathway or on β-catenin itself. However, western blot analysis using SW480 cells showed 
that β-catenin levels in both cytoplasmic and nuclear fractions were not affected. Some 
curcumin derivatives exhibiting Wnt/β-catenin pathway inhibitory activity were also 
reported to have no effect on β-catenin levels. Instead, they showed to decrease the level 
of p300, which is a positive regulator of the Wnt signal pathway.
17
 The FMCA was used 
to determine the effect of 1 and 8 on the viability of colon cancer cells, SW480, HCT116, 
and DLD1. Several studies previously reported that inhibiting TCF/β-catenin 
transcriptional activity decreased the viability of colon cancer cells.
17, 18
 However, after 
24 hr incubation, neither compounds exhibited inhibitory activity on the growth of these 
three colon cancer cells. 
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CHAPTER 4 
 
 
 
Cytotoxicity of Scopadulciol isolated from  
Scoparia dulcis against Wnt-dependent cancer cells 
  
 
 
4.1. Plant description 
S. dulcis belongs to the Plantaginaceae family. It is distributed in Thailand, 
Indonesia and Malaysia. Pharmacological studies showed that it possessed antidiabetic, 
anti-inflammatory and analgesic activities.
1
 Moreover, other studies had showed that 
scopadulciol isolated from this plant exhibited inhibitory activity against gastric H
+
, K
+
-
ATPase which is responsible for acid secretion in the stomach,
2
 and cytotoxicity against 
several gastric cancer cell lines.
3
 The plant sample (arial parts) used in this study was 
collected at Bangladesh and, a reference specimen (KKB304) has been deposited in the 
laboratory. The MeOH aerial plant extract of S. dulcis inhibited the TOP inhibitory 
activity by 73% at 5 µg/mL (Figure 4.1). At this concentration, it was not cytotoxic to the 
reporter cell (viability = 86%). 
 
 
Figure 4.1. Bar graphs showing the dose-dependent TOP activity of KKB304 
MeOH extract. The line graph represents cell viability. All data are 
presented as the mean ± s.d. (n=3). 
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4.2. Isolation of the constituents 
Figure 4.2 shows the isolation scheme of S. dulcis. The dried aerial parts of S. 
dulcis (128 g) were soaked in MeOH and left overnight at room temperature, 
homogenized, filtered and evaporated under reduced pressure to obtain a crude extract 
(3.0 g). The chlorophyll content of the MeOH crude extract was removed by Diaion HP-
20 column chromatography (φ 40 x 230 mm) using acetone:MeOH (0:1-1:0) and yielded 
three fractions (1A-1C). Fraction 1B (0.5 g), which was eluted with 100% MeOH and 
showed potent decrease in TOP activity, was subjected to silica gel column 
chromatography (φ40 x 275 mm) and eluted with CHCl3:MeOH gradient system (1:0 to 
0:1) to give fractions 2A-2K. Active fraction 2G (281.4 mg) eluted with CHCl3:MeOH 
(95:5) was subjected to silica gel column chromatography (φ40 x 280 mm) using 
CHCl3:MeOH gradient system (9:1 to 0:1) to give fractions 3A-3L. Fraction 3J (25.8 mg) 
eluted with CHCl3:MeOH (7:3) was further purified by preparative HPLC [Cosmosil 
5C18-AR-II; φ10 x 250 mm; 85% MeOH; 2 mL/min] to give compound 11 (5.6 mg, tR 
20.4 min). Fraction 1A (2.2 g) eluted with 100% MeOH was re-suspended in 10% MeOH 
(300 mL) and partitioned between n-hexane, EtOAc, and n-BuOH (300 mL x 3). The 
hexane fraction was then subjected to Sephadex LH-20 column chromatography (φ25 x 
250 mm) with MeOH to give fractions 5A-5E. Purification of fraction 5D by HPLC 
[Cosmosil Cholester; φ10 x 250 mm; 80% MeOH; 3 mL/min] yielded fractions 6A to 6D. 
Fraction 6B was identified as compound 12 (1.3 mg, tR 21.2). Fraction 6A (1.8 mg) was 
further purified by silica gel column chromatography (φ5 x 60 mm) and yielded 
compound 11 (1.5 mg). Recrystallization of fractions 2D, 2E and 3E in CHCl3/MeOH 
yielded compounds 13 (0.8 mg), 14 (0.5 mg) and, a mixture of β-sitosterol and β-
stigmasterol (0.8 mg), respectively. 
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Figure 4.2. Isolation chart of S. dulcis. 
 
 
 
4.3. Characterization of the isolated compounds 
Purification of the compounds by silica gel, ODS column chromatography, and 
HPLC afforded two scopadulan-type diterpene scopadulciol (11)
2
 and scopadiol (12)
4
, 
and two triterpenes friedelin (13) and glutinol (14). Their structures were identified by 
comparing their spectral values and optical rotations with those in the literature.  
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Scopadulciol (11)
2
 
1
H and 
13
C NMR see Table 4.1; [α]D
25
 -0.096 (c 0.5 CHCl3), lit. [α]D
23
 -2.3 (c 0.5 CHCl3);  
ESI-MS: m/z 447 [M+Na]
+ 
 871 [2M+Na]
+
  
Scopadiol (12)
4
 
1
H and 
13
C NMR see Table 4.1; [α]D
25
 -3.9 (c 0.5 CHCl3), lit. [α]D
26
 -2.7 (c 1.42 CHCl3); 
ESI-MS: m/z 449 [M+Na]
+ 
Friedelin (13) 
1
H and 
13
C NMR see Table 4.2; [α]D
25
 -1.5 (c 0.5 CHCl3), lit. [α]D -21 (c 0.51 CHCl3); 
ESI-MS m/z 449 [M+Na]
+ 
Glutinol (14) 
1
H and 
13
C NMR see Table 4.2; ESIMS: m/z 449 [M+Na]
+ 
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Table 4.1. NMR spectroscopic data of compounds 11 and 12 (in CDCl3). 
Position 
11 12 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1  34.2  38.5 
2  18.1  18.5 
3  38.4  38.3 
4  37.6  38.1 
5  43.0 2.03 (1H, br d, 3.0) 41.3 
6 5.61 (1H, br d, 1.8) 70.2 5.60 (1H, br d, 2.4) 71.5 
7  35.4 2.34 (1H, m) 36.9 
8 2.45 (1H, m) 35.8  144.3 
9  53.0  57.3 
10  39.0  38.7 
11  45.4  24.3 
12  52.3  38.3 
13      213.7  140.2 
14  42.7 5.40 (1H, t, 5.4) 123.2 
15  23.6 4.14 (2H, d, 7.2) 59.4 
16  36.6 1.66 (3H, s) 16.6 
17 0.90 (3H, s) 20.4 4.71 (2H, s) 113.0 
18 3.10 (1H, d, 11.1) 
3.57 (1H, d, 11.1) 
71.2 3.58 (1H, d, 11.4) 
3.13 (1H, d, 11.4) 
71.3 
19 1.06 (3H, s) 19.7 0.89 (3H, s) 20.3 
20 1.51 (3H, s) 21.7 1.44 (3H, s) 25.9 
21      166.3  166.2 
1’      130.6  130.8 
2’,6’ 8.01 (2H, d, 7.5) 129.6 8.01 (1H, d, 7.8) 129.6 
3’,5’ 7.43 (2H, t, 7.5) 128.5 7.42 (1H, t, 7.8) 128.4 
4’ 7.55 (1H, t, 7.3) 133.0 7.54 (1H, t, 7.8) 132.8 
 
 
 
 
 
 
 
12 11 
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Table 4.2. NMR spectroscopic data of compounds 13 and 14 (in CDCl3). 
Position 
13 14 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1 1.66 (1H, m) 
1.94 (1H, m) 
22.3 
 18.2 
2 2.28 (1H, m) 
2.37 (1H, ddd, 5.4, 1.8) 
41.5 
 27.8 
3  Not detected 3.45 (1H, m) 76.3 
4 2.23 (1H, m) 58.2  40.8 
5  42.1  Not detected 
6 1.26 (1H, m) 
1.73 (1H, m) 
41.3 
5.61 (1H, br d, 6.6) 122.1 
7 1.34 (1H, m) 
1.46 (1H, m) 
18.2 
 23.6 
8 1.38 (1H, m) 53.1  47.4 
9  37.4  34.9 
10 1.53 (1H, m) 59.5  49.7 
11 1.44 (2H, m) 35.6  34.6 
12 1.32 (2H, m) 30.5  30.4 
13   39.7  39.3 
14  38.3  37.8 
15 1.28 (1H, m)  
1.48 (1H, m) 
32.4 
 32.1 
16  36.0  36.0 
17  30.0  30.1 
18 1.55 (1H, m) 42.8  43.1 
19 1.18 (1H, m) 
1.34 (1H, m) 
35.3 
 35.1 
20  28.2  28.2 
21 1.42 (2H, m) 32.8  33.1 
22 0.92 (2H, m) 39.2  39.0 
23 0.86 (3H, d, 6.6) 6.8 1.02 (3H, s) 25.5 
24 0.70 (3H, s) 14.7 1.12 (3H, s) 28.9 
25 0.85 (3H, s) 17.9 0.83 (3H, s) 16.2 
26 0.98 (3H, s) 20.3 1.07 (3H, s) 19.6 
27 1.03 (3H, s) 18.7 0.98 (3H, s) 18.4 
28 1.16 (3H, s) 32.1 1.14 (3H, s) 32.0 
29 0.93 (3H, s) 35.0 0.93 (3H, s) 34.5 
 
 
14 13 
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4.4. TCF/β-catenin transcription inhibitory and cytotoxic activity of compound 11. 
The MeOH extract of S. dulcis (aerial part) was identified as a potential source of 
Wnt inhibitors during our screening of our plant extracts library using the TOP assay. Of 
the four isolated compounds, only 11 inhibited the TOP activity (Figure 4.3). However, 
11 also inhibited our FOP assay indicating that the TOP activity-inhibition in HEK293 
cells shown by 11 was not specific to TOP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Columns show the TOP and FOP activity of 11. TOP was measured using 
HEK293 cells stably transfected with SuperTOPflash reporter gene 
(STF/293) while the FOP activity was measured using HEK293 cells 
transiently transfected with SuperFOPflash reporter gene. Line graph 
represents the viability of STF/293 cells. Quercetin was used as the 
positive control for TOP assay. Data were from one experiment 
representative of at least two independent experiments (mean ± s.d). 
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However, 11 was observed to decrease the viability of the gastrointestinal cancer 
cells SW480 (colon), HCT116 (colon), DLD1 (colon), and AGS (gastric) cells which are 
reported to have an active Wnt signal and, RKO (colon) cells which is independent on β-
catenin for proliferation (Figure 4.4). It was also noted though that 11 showed some  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Effect of 11 on the viability of cancer cells AGS, RKO, SW480, HCT116, 
DLD1 and non-cancer cell HEK293. Cells were treated with 11 (300 nM) 
of different concentrations (125, 250 and 500 nM) for 24, 48 and 72 h. 
Viability was determined using FMCA and was calculated relative to 0 
day. 
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cytotoxicity against the non-cancer cell HEK293. Viability assay using FMCA showed 
that 11 greatly decreased the viability of RKO and AGS cells. Compound 11 caused 
higher decrease of viability in RKO cells (IC50 359 nM) than in AGS cells (IC50 500 nM) 
after 24 h (Table 4.3). However, RKO was observed to increase its viability after 48 h but 
for AGS, viability started to decrease.  
 
Table 4.3. IC50 values for the cytotoxic activity of 11. 
Time 
(h) 
IC50 (nM) 
SW480 HCT116 DLD1 AGS RKO HEK293 
24 >500 >500 >500 >500 359 >500 
48 >500 >500 >500 101 374 227 
72 296 >500 >500 70 479 181 
 
 
In addition, cell cycle analysis showed that 11 increased G0/G1 population in 
RKO cells after 24 h (Figure 4.5). On the other hand, treatment of AGS cells with 11 
resulted in a dose-dependent increase in Sub-G1 cell population suggesting that 11 
induced apoptosis. Meanwhile there was no observed change in the sub-G1 cell 
population in RKO even at 300 nM. Since 11 had showed to induce apoptosis in AGS 
cells, we then investigated whether the cytotoxic activity of 11 was dependent on caspase 
activity. In the presence of z-VAD-fmk, a pan caspase inhibitor, the cytotoxic activity of 
11 against AGS cells was not abolished indicating that the cytotoxic activity of 11 did not 
involve caspase activity (Figure 4.6). 
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Figure 4.5.  Effect of 11 on the cell cycle of RKO cells (upper panel) and AGS cells 
(lower panel). Cells were exposed to 11 (150 and 300 nM) for 24 h, 
stained with propidum iodide and analyses using FACS. 
Figure 4.6.  The involvement of caspase in the antiproliferative activity of 11 was 
determined by treating AGS cells with 11 in the absence or presence of 
z-VAD-fmk (50 µM), a pan-caspase inhibitor. Viability in both 
experiments was determined using FMCA and was normalized to 0 day. 
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CHAPTER 5 
 
 
 
Trichillins from Azadirachta excelsa inhibit  
Wnt/β-catenin transcriptional activity 
  
 
 
5.1. Plant description 
A. excelsa, commonly called marrango or Philippine Neem tree, belongs to the 
mahogany (Meliaceae) family. Similar to A. indica, it is also considered as a good source 
of compounds with antiinsecticidal properties such as azadirachtin and marrangin.
1
 
Pharmacological studies showed that it possessed antipyretic, antibacterial, antifungal and 
cytotoxic activities.
2
 Fruits of A. excelsa were used in this study, and were collected from 
Bangladesh. A reference specimen (KKB302) has been deposited in the laboratory. The 
TOP activity was inhibited by 79% at 10 µg/mL and the viability of the reporter cells was 
97% (Figure 5.1). 
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Figure 5.1. Bar graphs showing the dose-dependent TOP activity of KKB302 
MeOH extract. The line graph represents cell viability All data are 
presented as the mean ± s.d. (n=3). 
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5.2. Isolation of the constituents 
Figure 5.2 shows the isolation scheme of A. excelsa. The dried fruits of A. excelsa 
(204 g) were extracted with MeOH and yielded MeOH extract (30.5 g). The MeOH 
extract was resuspended in 10% methanol (300 mL) and partitioned between n-hexane, 
EtOAc, and n-BuOH (300 mL x 3) to give hexane (1.9 g), EtOAc (3.2 g), BuOH (6.5 g), 
and aqueous (14.7) extacts. The EtOAc fraction, which showed TOPflash inhibitory 
activity, was subjected to silica gel column chromatography (φ50 x 320 mm) using 
hexane:EtOAc gradient system (1:0 to 6:1) to give fractions 1A-1J, then followed by 
EtOAc-MeOH (1:1-0:1) to yield 1K-1M. Active fraction 1I (503.1 mg) eluted with 
hexane:EtOAc (0:1) was the subjected to ODS column chromatography (φ 40 x 230 mm) 
using MeOH (40-100%) to afford twelve fractions (2A-2L). Purification of fraction 2H 
(24.8 mg), from the eluate of 70-80% MeOH, by preparative HPLC [YMC-Pak-ODS-
AM; φ10 x 250 mm; 60% MeOH; 3 mL/min] gave compound 15 (1.5 mg, tR 18.0 min). 
Fraction 2F (29.2 mg) eluted with MeOH (50%) was further purified by HPLC [Cosmosil 
Cholester; φ10 x 250 mm; 60% MeOH; 3 mL/min], and yielded compound 17 (8.5 mg, tR 
15.0 min; 3.9 mg, 17.6 min). Fraction 2I (135 mg), from the eluate of 80% MeOH was 
further purified by sephadex column chromatography to give fractions 10A-10G. Fraction 
10D (31.4 mg) was subjected to HPLC [Cosmosil Cholester; φ10 x 250 mm; 65% MeOH; 
3 mL/min] to give compounds 16 (0.5 mg, tR 21.6 min), 18 (2.4 mg, tR 32.8 min), 21 (1.7 
mg, tR 37.6 min), and 22 (1.0 mg, tR 25.6 min). Fraction 10E (17.6 mg) was also subjected 
to HPLC [Cosmosil Cholester; φ10 x 250 mm; 65% MeOH; 2 mL/min] to give 
compounds 16 (0.3 mg, tR 26.0 min), 19 (1.1 mg, tR 48.0 min), 20 (1.1 mg, tR 57.0 min), 
21 (1.1 mg, tR 42.8 min), and 22 (0.8 mg, tR 30.2 min). 
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Figure 5.2. Isolation chart of A. excelsa. 
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5.3. Characterization of the isolated compounds 
Compound 15 was obtained as a colorless solid with a molecular formula of 
C34H44O12 based on HRESIMS (m/z  667.2742 C34H44O12Na,  Δ +1.1  mmu). Based from 
its IR spectra, absorption peaks at 3489 and 1743 cm
-1
 indicated the presence of hydroxyl 
and carbonyl groups, respectively. Its H and C NMR spectra had signals for a typical 
tetranortriterpenoid. The presence of peaks δH 7.17 (s), 7.36 (t), and 6.17 (brs) suggested 
the presence of a β-furan-ring. The presence of two acetate groups is indicated by signals 
at δH 1.99 (3H, s) and 2.08 (3H, s). Comparison of the NMR spectra of 15 and the 
reported compound 16, known as meliatoosenin I, showed that they had similar skeleton 
except for the ester moiety at C-29. In meliatoosenin I, 2-methylbutanoyl is attached to C-
29 while 15 had methylpropionyl group at this position. The attachment of the 
methylpropionyl group to C-29 was indicated by the HMBC correlation between H-29 
and C-1’.  
 
 
 
 
 
 
Based from the report of Fukuyama et al. (2006),
3
 downfield shifts of C-7 (81.2), C-14 
(97.5) and C-15 (77.0), from the shifts shown by compounds having 14,15-epoxide 
groups, indicated presence of an oxetane ring. On the other hand, the presence of 1-OH 
and 3-OAc was substantiated from the peak of 9-H at δ 4.48 which is due to the 1-OH in 
a 1,3-diaxial interaction. Compounds acetylated in H-1 were reported to show peak for H-
9 at δ 4.0-4.2. The small J values in H-1 and H-3 suggested that the 1-OH and 3-OAc  
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Table 5.1. NMR spectroscopic data of compound 15 and 16 (in CDCl3). 
Position 
15 16 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1 4.72 (1H, brs) 70.7 4.71 (1H, t, 3.6) 70.7 
2 5.87 (1H, t, 4.8) 68.8 5.87 (1H, t, 4.8) 68.8 
3 5.52 (1H, d, 4.8) 72.7 5.52 (1H, d, 4.8) 72.8 
4  41.5  41.5 
5 2.73 (1H, dd, 13.2, 5.4) 31.5 2.73 (1H, dd, 13.2, 6.0) 31.5 
6 1.78 (1H, m) 23.1 1.78 (1H, m) 23.1 
 1.92 (1H, m)  1.92 (1H, m)  
7 4.95 (1H, d, 3) 81.2 4.95 (1H, d, 2.4) 81.2 
8  45.2  45.2 
9 4.48 (1H, s) 52.1 4.48 (1H, s) 52.1 
10  39.8  39.8 
11  208.5  208.5 
12a 2.31 (1H, d, 19) 52.0 2.31 (1H, m) 52.0 
12b 2.48 (1H, d, 19)  2.48 (1H, m)  
13  46.2  46.3 
14  97.5  97.5 
15 4.89 (1H, s) 77.0 4.89 (1H, t, 4.2) 77.0 
16 1.97 (1H, m) 
1.87 (1H, m) 
37.6 1.95 (1H, m) 
1.87 (1H, m) 
37.7 
17 3.16 (1H, dd, 11.4, 5.4) 45.0 3.16 (1H, dd, 11.1, 5.4) 45.0 
18 1.03 (3H, s) 21.6  21.6 
19 4.05,4.02 (2H, ABq, 12) 64.2 4.05,4.02 (2H, d, ABq, 12) 64.2 
20  124.1  Not detected 
21 7.17 (1H, s) 139.5 7.16 (1H, s) 139.5 
22 6.17 (1H, brs) 110.9 6.17 (1H, s) 110.9 
23 7.36 (1H, t, 1.8) 143.1 7.36 (1H, t, 1.2) 143.1 
28 0.77 (3H, s) 17.1  17.0 
29 5.69 (3H, s) 92.7 5.70 (1H, s) 92.6 
30 1.23 (3H, s) 17.0 1.23 (3H, s) 17.0 
2-CH3CO 
2-CH3CO 
1.99 (3H, s) 20.7 
168.9 
1.99 (3H, s) 20.7 
168.8 
3-CH3CO 
3-CH3CO 
2.08 (3H, s) 20.9 
170.1 
2.08 (3H, s) 20.9 
170.1 
1’  175.7  Not detected 
2’ 2.59 (1H, quin, 7) 34.1 2.47 (1H, m) 41.0 
3’ 
 
1.20 (3H, d, 7) 
 
18.7 
 
1.68 (1H, quin, 7.8) 
1.53 (1H, m) 
26.5 
4’ 1.18 (3H, d, 7) 18.6 1.16 (3H, d, 6.6) 16.3 
5’   0.91 (3H, t, 7.8) 11.3 
1-OH 2.29 (1H, brs)  2.31 (1H, overlapped)  
 
56 
 
functional groups were in axial and α-configuration.3 The S-configuration at C-29 was 
determined based from the chemical shift at H-3. The chemical shift in 15 at H-3 is  
δ 5.52 which would suggest that the methylpropanoyl group is at the exo-position. As 
discussed by Huang et al. (1994),
4
 in general, 3-H signal appears upfield (example δ 4.87 
endo-toosendanin) in the endo-configuration as compared to the exo-isomer (δ 5.33 exo-
toosedanin) (Table 5.2). 
The structures of the other known limonoids were identified by comparing their 
spectral values and optical rotations with those in the literature.  
 
Meliatoosenin I (16)
5
 
1
H and 
13
C NMR see Table 5.1; [α]D
25
 -55.7 (c 0.10 MeOH), lit. [α]D
18
 -51.0 (c 0.14 
MeOH); ESIMS:  m/z 681 [M+Na]
+
 
Toosendanin [C-29 epimeric mixture (1:1), 17]
6
 
1
H and 
13
C NMR see Table 5.2; ESI-MS: m/z 597 [M+Na]
+
 1171 [2M+Na]
+
  
Trichillin H (18)
7
 
1
H and 
13
C NMR see Table 5.2; [α]D
25
 -76.1 (c 0.19 MeOH), lit. [α]D -20.2 (c 0.12) 
MeOH); ESIMS:  m/z 725 [M+Na]
+
 
12-O-acetylazedarachin B (19)
4
 
1
H and 
13
C NMR see Table 5.3; [α]D
24
 -16.2 (c 0.10 MeOH), lit. [α]18D -55.0 (c 0.13 
MeOH); ESIMS:  m/z 667 [M+Na]
+
  1311 [2M+Na]
+
    
Meliatoxin A1 (20)
8, 9
 
1
H and 
13
C NMR see Table 5.3; [α]D
25
 -144.5 (c 0.10 MeOH); CD (MeOH): 230 nm (Δε 
+0.7), 299 (Δε -4.8), lit. CD (MeOH): 222 nm (Δε +1), 294 (Δε -4.8); ESIMS:  m/z 681 
[M+Na]
+
  1339 [2M+Na]
+ 
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Meliatoxin B2 (21)
8, 9 
1
H and 
13
C NMR see Table 5.4; [α]D
24
 -37.8 (c 0.19 MeOH); CD (MeOH): 214 nm (Δε 
+6.9), 299 (Δε -3.0), lit. CD (MeOH): 225 nm (Δε +6), 293 (Δε -4.8); ESIMS:  m/z 667 
[M+Na]
+ 
Meliatoxin B1 (22)
8, 9
 
1
H and 
13
C NMR see Table 5.4; [α]D
24
 -47.7 (c 0.14 MeOH); CD (MeOH): 209 nm (Δε 
+6.2), 298 (Δε -3.8), lit. CD (MeOH): 224 nm (Δε +5), 293 (Δε -4.7); ESIMS:  m/z 681 
[M+Na]
+ 
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Table 5.2. NMR spectroscopic data of compounds 17 and 18 (in CDCl3). 
Position 17 (endo-) [29-epimer (exo-)] (1:1) 18 
 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 
1 4.25 (1H,brm) [4.30 (1H,br m)] 70.3 4.40 (1H, brt, 4.2) 
2 2.82 (2H,dt,16.8, 4.5) 35.4 [36.1] 5.88 (1H, t, 4.8) 
3 4.87 (1H,d,4.5) [5.33 1H,d,4.5] 73.6 [76.3] 5.51 (1H, d, 4.8) 
4  40  
5 2.48-2.617 m 25.5 [27.9] 2.79 (1H, dd, 13.8,3.6) 
6  25.4 [27.3] 1.71 (1H, dt, 14.4,3.6) 
2.01 (1H, m) 
7 3.58 (1H,brm) [3.62 (1H,brm)] 70.5 3.66 (1H, s) 
8  42.4 [42.5]  
9 4.56 (1H, s) 48.3 [48.6] 4.61 (1H, s) 
10  41.7  
11  206.8  
12 5.29 (1H, s) 78.4 [78.7] 5.40 (1H, s) 
13  45.7  
14  72.1 [72.3]  
15 3.74 s 58.7 3.75 (1H, s) 
16 2.21 (2H,dd, 13.5, 7.2) 33.6 2.22 (1H, dd, 13.6, 6.6) 
1.88 (1H, dd, 13.6, 11.4) 
17 2.94 (1H, dd, 11.4, 7.2) 38.2 2.97 (1H, dd, 11.4, 6.0) 
18 1.29 (3H, s) [1.30 (3H, s)] 20.7 1.33 (3H, s) 
19 4.16 (1H, d, 12.3) [4.29 (1H, d, 12.3)] 
4.22 (1H, d, 12.3) [4.47 (1H, d, 12.3)] 
58.7 [63.8] 4.29,4.36 (2H, ABq, 13.6) 
20  122.5  
21 7.10 (1H, s) 142.4 7.11 (1H, s) 
22 6.11 (1H, s) 111.9 6.11 (1H, s) 
23 7.31 (1H, s) 140.6 7.32 (1H, t, 1.2) 
28 0.86 (3H, s) [0.87 (3H, s)] 15.6 0.82 (3H, s) 
29 4.76 (1H, s) [4.86 (1H, s)] 96.1 [96.4] 5.73 (1H, s) 
30 1.13 (3H, s) [1.16 (3H, s)] 18.5 [19.6] 1.15 (3H, s) 
2-COCH3   2.00 (3H, s) 
3-COCH3 
3-COCH3 
2.07 (3H, s) [2.08 (3H, s)] 22.5 [22.7] 
170.2 [170.1] 
2.11 (3H, s) 
12-COCH3 
12-COCH3 
1.96 (3H, s) [1.97 (3H ,s)] 
 
21.4 [21.5] 
169.8 
1.96 (3H, s) 
2’   2.67 (1H, hept, 7.0) 
3’   1.22 (3H, d, 7.0) 
4’   1.21 (3H, d, 7.0) 
1-OH 2.27 (1H,d,7.2) [2.31 (1H,d,7.2)]  2.51 (1H, d, 4.0) 
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Table 5.3. NMR spectroscopic data of compounds 19 and 20 (in CDCl3). 
Position 
19  20 
1
H (600 MHz)  
1
H (600 MHz) 
1 4.25 (1H, t, 4.2)  4.22 (1H, t, 4.2) 
2 1.89 (1H, m) 
2.80 (1H, dt, 16.8, 4.8) 
 5.89 (1H, t, 4.2) 
3 5.29 (1H, d, 3.6)  5.50 (1H, d, 4.2) 
4    
5 2.70 (1H, dd, 14.7, 4.2)  2.73 (1H, m) 
6 1.71 (1H, dt, 13.8, 4.8) 
2.00 (1H, m) 
 1.70 (1H, m) 
~2.0 (1H, m) 
7 3.67 (1H, m)  3.67 (1H, brs) 
8    
9 4.59 (1H, s)  4.58 (1H, s) 
10    
11    
12 5.26 (1H, s)  2.44 (2H, s) 
13    
14    
15 3.74 (1H, s)  3.69 (1H, s) 
16 2.22 (1H, dd, 6.9, 0.6) 
1.89 (1H, m) 
 
 2.24 (1H, dd, 13.2, 6.3) 
1.86 (1H, dd, 13.2, 11.4) 
 
17 2.96 (1H, dd, 11.0, 7.2)  2.73 (1H, m) 
18 1.30 (3H, s)  1.22 (3H, s) 
19 4.27, 4.4.30 (2H, ABq, 13.2)  4.37, 4.4.45 (2H, ABq, 13.2) 
20    
21 7.11 (1H, brd, 0.6)  7.12 (1H, s) 
22 6.13 (1H, t, 0.6))  6.11 (1H, s) 
23 7.30 (1H, t, 1.8)  7.36 (1H, t, 1.5) 
28 0.81 (3H, s)  0.82 (3H, s) 
29 5.78 (1H, s)  5.76 (1H, s) 
30 1.15 (3H, s)  1.07 (3H, s) 
2-COCH3   2.01 (3H, s) 
3-COCH3 2.08 (3H, s)  2.11 (3H, s) 
12-COCH3 1.97 (3H, s)   
2’ 2.60 (1H, hept, 6.6)  2.49 (1H, m) 
3’ 1.18 (3H, d, 7.2)  1.53 (1H, m) 
1.70 (1H, m) 
4’ 1.17 (3H, d, 7.2)  1.17 (3H, d, 6.6) 
5’   0.92 (3H, t, 7.1) 
1-OH   2.37 (1H, d, 4.2) 
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Table 5.4. NMR spectroscopic data of compounds 21 and 22 (in CDCl3). 
Position 
21 22 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1 4.25 (1H, d, 4.8) 71.9 4.26 (1H, d, 4.2) 71.9 
2 5.88 (1H, t, 4.8) 68.7 5.88 (1H, t, 4.2) 68.7 
3 5.55 (1H, d, 4.8) 73.3 5.56 (1H, d, 4.2) 73.3 
4  40.6  40.7 
5 2.65 (1H, m) 28.1 2.63 (1H, m) 28.1 
6 1.82 (1H, dt, 14.4, 4.2) 23.0 1.81 (1H, dt, 13.8, 4.2) 
2.10 (1H, m) 
23.0 
7 3.96 (1H, brs) 69.2 3.96 (1H, m) 69.2 
8  43.1  43.1 
9 3.46 (1H, s) 51.4 3.46 (1H, s) 51.4 
10  42.6  42.6 
11  209.9  209.9 
12 2.29, 2.65 (2H, ABq, 17.4) 43.3 2.29, 2.65 (2H, ABq, 17.4) 43.3 
13  44.8  44.8 
14 3.14 (1H, s) 62.4 3.14 (1H, s) 62.4 
15  219.4  219.4 
16 2.56 (2H, d, 10.4) 50.5 2.56 (2H, d, 10.2) 50.5 
17 3.32 (1H, t, 10.4) 41.8 3.32 (1H, t, 10.2) 41.8 
18 1.02 (3H, s) 28.1 1.03 (3H, s) 28.1 
19 4.16,4.62 (2H, ABq, 12.6) 63.8 4.16,4.64 (2H, ABq, 13.2) 63.8 
20  121.7  121.7 
21 7.30 (1H, d, 0.6) 140.2 7.3 (1H, s) 140.2 
22 6.22 (1H, dd, 1.8, 0.6) 110.2 6.28 (1H, s) 110.2 
23 7.40 (1H, t, 1.8) 143.4 7.40 (1H, t, 1.2) 143.4 
28 0.84 (1H, s) 18.5 0.84 (3H, s) 18.4 
29 5.76 (1H, s) 93.0 5.74 (1H, s) 93.1 
30 0.97 (3H, s) 20.2 0.97 (3H, s) 20.2 
2-CH3CO 
2-CH3CO 
2.01 (3H, s) 20.8 
169.0 
2.01 (3H, s) 20.8 
169.0 
3-CH3CO 
3-CH3CO 
2.12 (3H, s) 20.9 
169.9 
2.11 (3H, s) 20.9 
169.9 
1’  175.3  n.d. 
2’ 2.46  (1H, m) 41.0 2.63 (1H, m) 34.1 
3’ 1.53, 1.68 (2H, m) 26.5 1.20 (3H, d, 6.9) 18.8 
4’ 1.17 (3H, d, 7.2) 11.3 1.19 (3H, d, 6.9) 18.7 
5’ 0.92 (3H, t, 7.8) 16.3   
1-OH 2.45 (1H, d, 4.8)  2.44 (1H, d, 4.8)  
6-OH 2.74 (1H, brs)  2.73 (1H, d, 5.4)  
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5.4. TCF/β-catenin transcription inhibitory activity of the isolated compounds 
All the limonoids isolated from A. excelsa showed inhibitory activity against TOP 
activity. Compounds 17-20 showed the strongest inhibitory activity with IC50 values 127, 
300, 252 and 121 nM, respectively (Figure 5.3 and Table 5.5). Moreover, these 
compounds did not significantly affect FOP indicating that they specifically inhibited 
TOP.  
 
 
Figure 5.3. Columns show the TOP and FOP activity of 17-20. TOP was measured 
using HEK293 cells stably transfected with SuperTOPflash reporter 
gene (STF/293) while the FOP activity was measured using HEK293 
cells transiently transfected with SuperFOPflash reporter gene. Line 
graph represents the viability of STF/293 cells. Data were from one 
experiment representative of at least two independent experiments 
(mean ± s.d). 
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We then did simple structure-activity relationships study on the eight compounds isolated. 
It was observed that compounds bearing the 14,15-epoxide moiety had IC50 values at the 
nanomolar scale, while the other compounds had IC50 values at the micromolar scale. 
Possibly, the 14,15-epoxide moiety is an important functional group in the inhibition of 
the TOP activity. 
 
 
Table 5.5. Structure-activity relations of compounds 15-22.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TOP inhibitory activity 
IC50 (µM)           IC50 (nM) IC50 (µM) 
15            33.7 
16            20 
17            127 
18            300 
19            252 
20            121 
21             14.8 
22             36.7 
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5.5. Cytotoxic activity of compounds 17-19 
 We then investigated the cytotoxic activity of compounds 17-19 against 
gastrointestinal cancer cells SW480 (colon), HCT116 (colon), DLD1 (colon) and AGS 
(gastric) which all possess an active Wnt signal. We also determined their cytotoxic 
activity in Wnt-independent colon cancer RKO and a non-cancer cell line HEK293. It 
was observed that after 48 h treatment, the compounds had cytotoxicity against HCT116 
(Figure 5.4). Compound 17 had the strongest cytotoxicity with IC50 24.9 nM. But, it was  
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Figure 5.4. Effect of 17-19 on the viability of cancer cells AGS, RKO, SW480, HCT116, 
DLD1 and non-cancer cell HEK293. Cells were treated with the compounds 
of different concentrations (100, 200 and 400 nM) for 48 h. Viability was 
determined using FMCA. 
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also observed that 17 affect the viability of the Wnt-independent RKO. Compound 19 
also decreased the viability of HCT116 and RKO. Compound 18 was observed to exhibit 
cytotoxicity in Wnt-dependent AGS and HCT116. Though its IC50 values for these two 
cancer cells were lower than the observed IC50 of the either compound 17 or 19, its IC50 
for the Wnt-independent RKO as well as for the non-cancer cell line was >400 nM (Table 
5.6). Furthermore, compounds 17-19 did not greatly decrease viability of SW480 and 
DLD1 (IC50 >400 nM). 
 
 
Table 5.6. IC50 for the cytotoxic activity of compounds 17-19. 
 
Non-cancer cell 
Cancer cells 
Wnt-independent Wnt-dependent 
HEK293 RKO AGS HCT116 SW480 DLD1 
17 >400 129 192      24.9 >400 >400 
18 >400 >400 239 161 >400 >400 
19 >400 331 >400 108 >400 >400 
 
 
5.6. Effect of 18 on the β-catenin and c-myc level in HCT116 
 Compound 18 showed cytotoxicity activity against HCT116, which harbor mutant 
β-catenin and wild-type APC, and not in SW480 and DLD1 which both have truncated 
APC and wild-type β-catenin. From this result, we inferred that the activity of 18 in 
HCT116 was possibly APC-mediated. However, western blot analysis showed that 18 did 
not degrade β-catenin, and also it did not affect the localization of β-catenin in HCT116 
(Figure 5.5). This result suggested that APC may have not mediated the inhibition of Wnt 
signal by 18. Wild-type APC has been reported to control nuclear accumulation of β-
catenin by a combination of nuclear export and cytoplasmic degradation.
10
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 On the other hand, compound 18 decreased the level of the TCF/β-catenin target 
protein, c-myc. This result indicated that even though there 18 did not affect level of β-
catenin, possibly, it inhibited the Wnt signal affecting downstream of β-catenin. Moreover, 
the data suggested that the inhibitory activity of 18 was not mediated through induction of 
nuclear export and/or degradation of β-catenin. It can be implied that the action of 18 may 
have affected the downstream components of β-catenin. Inside the nucleus, β-catenin 
forms a complex with TCF which then recruits other co-activators pygopus, CBP and 
Bcl9 to activate the transcription process.
11
 However, it was also reported that C-terminal 
binding protein (CtBP) can lower the available free nuclear β-catenin for binding to TCF 
by sequestering APC/β-catenin complex.12 Possibly, the Wnt signal inhibitory action of 
18 could be targeting the TCF/β-catenin complex formation.  We assume also the possible 
involvement of nuclear CtBP as it was shown that CtBP preferentially binds to full-length 
APC, and not with truncated APC,
13
 which may explain why 18 did not affect the 
viability of SW480 and DLD1.  
β-catenin (92 kDa) 
c-myc (33 kDa) 
β-actin (42 kDa) 
Histone H1 (33-34 kDa) 
18 (nM) 0     200  400   800 
Cytoplasmic Nuclear 
0     200  400    800 
 
 
 
 
 
Figure 5.5. Western blot analysis of β-catenin and c-myc in HCT116 cells treated 
with 18 for 24 h. Cytoplasmic and nuclear lysates from HCT116 cells 
were obtained and subjected to Western blot analysis with anti-β-catenin 
and anti-c-myc antibodies. β-actin serves as protein control for full and 
cytoplasmic fractions while histone H1 for the nuclear fraction.   
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CHAPTER 6 
 
 
 
Scopadulciol (11) induces β-catenin degradation in  
AGS human gastric adenocarcinoma cells 
  
 
 
6.1. Rationale 
  Compound 11 was not identified as a “positive” compound using the STF/293 
assay system. In our study, however, we observed that 11 can affect the viability of AGS 
(gastric) and RKO (colon) cells. Previous report had shown that scopadulciol (11) 
exhibited cytotoxic activity against some gastric cancer cell lines.
1
 However, its 
mechanism of action has not been reported. As discussed in Chapter 4, compound 11 
caused a G0/G1 arrest in RKO cells while it induced apoptosis in AGS cells after 24 h. 
However, RKO was able to recover from the effect of 11 at 48 h while it caused 
decreased viability in AGS. But, z-VAD-fmk, a pan-caspase inhibitor, did not reverse the 
anti-proliferative activity of 11 in AGS which suggested that the apoptotic action of 11 
was independent of the caspase activity. Because of these observed results, we then 
investigated the participation of the Wnt/β-catenin signal in the antiproliferative activity 
of 11 in AGS. 
 
6.2. Scopadulciol induces degradation of β-catenin level in AGS 
AGS has an active Wnt signalling pathway due to mutation in β-catenin (G34E).2  
As shown in Figure 6.1, 11 decreased the β-catenin level in AGS cells after 24 h exposure 
in a concentration-dependent manner. Moreover, it inhibited the β-catenin accumulation 
in the nucleus as shown by the decrease in the level of nuclear β-catenin. From these 
results, we can infer that 11 could be affecting the Wnt signal. Then, we investigated the  
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possible mechanism involved in the β-catenin degradation by 11. In the Wnt signalling 
pathway, the phosphorylation of β-catenin by CK1α and GSK3β is an important step in 
the ubiquitin/proteasome-mediated degradation of β-catenin.3, 4 However, we observed 
that the level of GSK3β as well as the phosphorylated β-catenin was decreased in the 
presence of 11 (Figures 6.2a and 6.2b). CK1α was not significantly affected by 11. These 
results suggested that the degradation of β-catenin by 11 was independent of GSK3β. 
 
β-catenin (92 kDa)  
     0    100    200    400 11 (nM) 
β-actin (42 kDa)  
 
Full 
  
 
 
 0      100    200   400  0      100    200   400 
Histone H1 (33 kDa) 
Cytoplasmic Nuclear 
Figure 6.1.   Effect of 11 on the level and localization of β-catenin in AGS after treatment 
with different concentrations of 11 (100, 200, 400 nM) for 24 h. Whole cell, 
cytoplasmic and nuclear lysates from AGS cells were obtained and subjected 
to Western blot analysis with anti-β-catenin antibody. β-actin serves as 
protein control for full and cytoplasmic fractions while histone H1 for the 
nuclear fraction. 
 
Figure 6.2. Western blot analysis on the level of (a) GSK3β and CK1α, and (b) 
phosphorylated β-catenin in AGS cells after treatment with different 
concentrations of 11 (100, 200, 400 nM) for 24 h. 
GSK3β (47 kDa)  
     0     100    200   400 11 (nM) 
β-actin (42 kDa)   
 CK1α (34 kDa) 
pβ-catenin (S33,  
S37, T41) (92 kDa) 
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pβ-catenin (S45) 
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6.3. Degradation of β-catenin by 11 is mediated by proteasome activity. 
The mutation of β-catenin (G34E) in AGS is suggested to reduce the efficiency of 
the ubiquitin-proteasome degradation of β-catenin.2 We then investigated if degradation 
of β-catenin in AGS by 11 is mediated by proteasomal activity. The proteasome activity 
was inhibited by pre-treatment of AGS with either MG132 or epoxomicin for 1 h. MG132 
and epoxomicin are both 26S proteasome inhibitors, but epoxomicin is a more specific 
inhibitor.
5
 After pre-treatment with the proteasome inhibitors, the cells were treated with 
11 for 24 h. Treatment with either MG132 or epoxomicin alone did not affect the level of 
β-catenin. In AGS treated with 11, pre-treatment with MG132 or epoxomicin abolished 
the degradation of β-catenin. The result indicated that the 11-induced degradation of β-
catenin is proteasome-dependent (Figures 6.3a and 6.3b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 β-actin (42 
kDa) 
β-catenin (92 kDa) 
MG132 (10 µM) 
11 (400 nM) 
   -         +         -         + 
   -         -          +        + 
 
 β-actin (42 kDa) 
kDa) 
β-catenin (92 kDa) 
Epoxomicin (10 µM) 
11 (400 nM) 
   -         +         -         + 
   -         -          +        + 
a 
b 
Figure 6.3. Effect of (a) MG132 and (b) epoxomicin on β-catenin level in AGS 
cells treated with 11. Cells were pre-treated with either MG132 (10 
µM) or epoxomixin (10 µM) for 1 h and treated with 11 (400 nM) for 
24 h. 
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Moreover, β-catenin had been reported to be protealytically cleaved by proteases 
calpain and calpase during apoptosis.
6-8
 To determine the participation of the proteases in 
β-catenin degradation, we pre-treated AGS with either a pan-caspase inhibitor, z-VAD-
fmk, or with the calpain inhibitor calpastation for 1 h. After the pretreatment, AGS cells 
were then treated with 11. Pre-treatment with either caspase-inhibitor or the calpain 
inhibitor did not protect the degradation of β-catenin by 11 (Figure 6.4a and 6.4b). This 
indicated that caspase and calpain were not involved in the β-catenin degradation by 11.  
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4. p53 is involved in the degradation of β-catenin by scopadulciol (11) 
 p53 has been reported to decrease the stability of β-catenin independent of GSK3β 
and β-TrCP via the Siah-1 mechanism.9, 10 We then investigated the possible role of p53 
in the 11-induced degradation of β-catenin. AGS cells were treated with 11 in the absence 
or presence of pifithrin-α, a p53 transcriptional activity inhibitor,11 for 24 h. Western blot 
 
 β-actin (42 kDa) 
β-catenin (92 kDa) 
z-VAD-fmk (50 µM) 
11 (400 nM) 
   -        +       -         + 
   -        -        +        + 
 
 β-actin (42 kDa) 
β-catenin (92 kDa) 
Calpastatin (10 µM) 
11 (400 nM) 
   -        +       -         + 
   -        -        +        + 
a 
b 
Figure 6.4. Effect of (a) z-VAD-fmk and (b) calpastatin pretreatment on β-
catenin level in AGS cells treated with 11. Cells were pre-treated 
with either z-VAD-fmk (50 µM) or calpastatin (10 µM) for 1 h and 
treated with 11 (400 nM) for 24 h. 
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analysis showed that pifithrin-α abolished the degradation of β-catenin by 11, while β-
catenin level in AGS cells treated with pifithrin-α alone was unaffected (Figure 6.5). The 
results suggested that p53 mediated the degradation of β-catenin induced by 11. 
 
 
 
 
 
 
 
 
 
 
Since the phosphorylation/β-TrCP pathway was observed to be involved in the β-
catenin degradation by 11 in AGS, 11 may have affected other mechanism that can 
induce degradation of β-catenin. One possible pathway is via the Siah-1 mechanism in 
which β-catenin is degraded independent of GSK3β and β-TrCP and can be induced by 
the activity of p53.
9, 10
 Since we observed that p53 also mediated the degradation of β-
catenin by 11, possibly, the Siah-1 mechanism is involved. 
 
6.5. Scopadulciol (11) inhibits TCF/β-catenin transcriptional activity and 
downregulates the expression of β-catenin target proteins in AGS. 
The decrease of β-catenin level by 11, particularly in the nucleus, also suggested 
that TCF/β-catenin transcriptional activity was also inhibited. The TCF/β-catenin 
transcriptional activity regulates the expression of proliferation and survival proteins such 
 
 β-actin (42 kDa) 
β-catenin (92 kDa) 
Pifithrin-α (20 µM) 
11 (200  nM) 
   -         +         -         + 
   -         -          +        + 
Figure 6.5. Level of β-catenin in AGS treated with 11 (200 nM) for 
24 h in the absence or presence of pifithrin-α (20 µM), 
p53 transcriptional activity inhibitor 
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as c-myc, cyclin D1 and survivin. We then transfected AGS cell with the reporter plasmid 
TOPflash or the negative reporter, FOPflash, and treated the cells with 11. As shown in 
Figure 6.6, the TOPflash activity was inhibited without a significant effect on the 
FOPflash activity suggesting that the inhibition was specific to TOPflash activity. This 
result indicated that the β-catenin/TCF activity was inhibited in the presence of 11 in 
AGS.  
 
 
 
 
 
 
 
 
 
We then determined the expression level of the β-catenin-dependent target 
proteins cyclin D1,
12
 c-myc
13
 and survivin.
14
 Western blot analysis (Figure 6.7) showed 
that 11 decreased the level of cyclin D1, c-myc and survivin in a dose-dependent manner, 
suggesting further that 11 inhibited the TCF/β-catenin transcriptional activity in AGS 
cells.   
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Figure 6.6. TOP and FOP activity of 11 in AGS cells. AGS cells were co-
transfected with either TOP or FOP reporter gene and pRL-CMV 
plasmids for 24 h. After transfection, cells were incubated with 11. 
Luciferase activities were measured after 24 h post-transfection.  
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6.6. Scopadulciol (11) exerted p53-dependent cytotoxicity in AGS 
 Since p53 was identified to mediate the degradation of β-catenin by 11, we then 
determined if inhibition of the p53 activity will also affect the cytotoxic activity of 11. 
We treated the AGS cells with 11 in the absence or presence of pifithrin-α for 48 h. Based 
from FMCA, we observed that pifithrin-α abrogated the cytotoxic activity of 11 in AGS 
(Figure 6.8). The result suggested that 11 exerted p53-dependent cytotoxic activity in 
AGS cells.  
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Figure 6.7. Western blot analysis using full lysate on the level of TCF/β-catenin 
target proteins in AGS cells after treatment with different 
concentrations (100, 200, 400 nM) of 11 for 24 h. Whole cell lysate 
were obtained and subjected to Western blot analysis. 
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Figure 6.8. Effect pifithrin-α (20 µM) on the viability of AGS treated with 11 
(100 nM) for 48 h. Viability of AGS was measured using FMCA. 
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CHAPTER 7 
 
 
 
Scopadulciol (11) sensitizes AGS to  
TRAIL-induced apoptosis 
  
 
 
7.1. Background of the study 
Targeting β-catenin has also been suggested as another possible strategy to 
enhance the TRAIL-mediated apoptosis in resistant cancer cells.
1
 The use of tumor 
necrosis factor-related apoptosis ligand (TRAIL) to induce cancer cell apoptosis has been 
considered an attractive strategy as it affects the cancer cell and not the normal cells.
2
 
When TRAIL binds to the death receptors (DR4 and DR5), it leads to the activation of 
Fas-associated death domain (FADD), followed by the activation of effector caspase 
(caspase-3) by the initiator caspase (caspase-8) (Figure 7.1).
3
 Also, TRAIL-induced 
apoptosis requires the mitochondrial pathway to completely activate caspase-3.
4
 When 
the caspase-8 is activated, truncated Bid (tBid) is generated which then translocates to the 
mitochondria. Interaction of the tBid with Bax and Bak results in the release of 
cytochrome c and SMAC/DIABLO, and induces apoptosis.  
However, several cancer cells have developed resistance to the effect of TRAIL 
due to the overexpression of decoy receptors or of anti-apoptotic proteins such as Bcl2 
and IAPs (e.g. survivin).
5
 Treatment with combination of TRAIL and compounds that can 
either upregulate DR4 or DR5 expression or downregulate the antiapoptotic protein level 
are possible strategies to overcome TRAIL-resistance in cancer cells. Several reports had 
shown that β-catenin can be a potential target to sensitize TRAIL-resistant cancer cells. In 
this study, we investigated to determine if 11 can sensitize AGS to TRAIL-induced 
apoptosis.  
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7.2. Scopadulciol (11) has TRAIL-resistance overcoming activity. 
The AGS cancer cell line is known to have a strong resistance to TRAIL. 
Treatment of AGS with TRAIL (100 ng/mL) did not significantly reduced the viability. 
When TRAIL was administered with luteolin
6
 (17.7 µM), which was used as a positive 
control, the viability was further decreased to 41%. Combined treatment of 11 and 
TRAIL synergistically exhibited stronger apoptosis induction activity on AGS than in the 
Figure 7.1.   Intrinsic and extrinsic TRAIL (tumor necrosis-
related apoptosis inducing ligand) signaling 
pathway. 
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treatment with 11 alone (Figure 7.2). After 24 h exposure, combined treatment of 11 (200 
nM) and TRAIL (100 ng/mL) showed about 93% reduction in AGS viability. 
 
 
 
 
 
 
 
 
 
 
FACS analysis showed that at 12 h exposure, 27.7% apoptotic cells were observed 
in 11+TRAIL combined treatment while only 5.7% and 3.5% were observed in treatment 
with TRAIL or 11 alone, respectively (Figure 7.3). Furthermore, the number of early 
apoptotic cells in AGS with either TRAIL or 11 alone did not show significant difference 
with the control. These results suggested that 11 had a strong TRAIL-resistance 
overcoming activity. Furthermore, the combined treatment of non-cancer cell line 
HEK293 with 11 and TRAIL showed lower reduction in viability as compared with AGS 
(Figure 7.4). 
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Figure 7.2. Compound 11 showed TRAIL-overcoming resistance activity in AGS 
cells. Cells were exposed to the different treatments as described for 
24 h and assayed for viability using FMCA. Lut = Luteolin serves as 
control for the TRAIL-overcoming resistance activity assay. 
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Figure 7.3. FACS analysis on the induction of apoptosis in AGS cells by TRAIL+11 
combined treatment. Cells were exposed to the different conditions as 
described for 12 h. Cells were collected and stained with annexin V and 
propidium iodide. The population of viable, apoptotic and dead cells were 
quantified by FACS analysis. 
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Figure 7.4. Effect of combined treatment of TRAIL and 11 against non-cancer 
cell HEK293. Cells were exposed to the different treatments as 
described for 24 h. Viability was determined using FMCA and was 
normalized to control (0 nM). 
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7.3. Scopadulciol (11) affected the level of the apoptosis-related proteins 
Western blot analysis showed that 11 increased the level of DR4 and DR5 (Figure 
7.5a), and decreased the level of the anti-apoptotic proteins Bcl2 (Figure 7.5a). 
Compound 11 was also observed to increase p53 level in AGS. Since in TRAIL-induced 
apoptosis caspase is responsible in initiating apoptosis, we then determined if the 
decrease in viability depends on the caspase activity. We pre-treated AGS cells with z-
VAD-fmk, a pan-caspase inhibitor, for 1 h and then, treated with 11 in the absence or 
presence of TRAIL for 24 h. Results showed the caspase-inhibitor blocked the apoptosis 
induced by the combined treatment 11+TRAIL, suggesting that the effect of 11 and 
TRAIL is caspase-dependent (Figure 7.5b).  
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Figure 7.5. (a) Western blot analysis of p53, DR4, DR5 and Bcl2 in AGS treated with 
different concentration of 11. Cells were treated with 11 at different 
concentrations (50, 200, 400 nM) for 24 hr and analyzed by Western blot.  
(b) Effect of z-VAD-fmk (50 µM) on the viability of AGS cells treated with 
combined TRAIL and 11. Cells were pretreated with z-VAD-fmk (50 µM) for  
1 h, then treated as described for 24 h. Viability was calculated relative to the 
control (no inhibitor and TRAIL) treatment. Data are from one experiment 
representative  of at least two independent experiments (mean ± s.d.). 
 
a b 
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The increase in the DR4 and DR5 level could lead to an enhance binding of 
TRAIL to the death receptors. The binding of TRAIL to the death receptors leads to the 
activation of caspase-8 which then activates caspase-3 to mediate apoptosis.
3
  Moreover, 
the mitochondrial pathway further enhanced the 11+TRAIL induced apoptosis as 11 was 
observed to decrease the level of Bcl2 and survivin. Bcl2 is known to inhibit the pro-
apoptotic protein Bax while survivin inhibits the activation of procaspase-9 to caspase-3.
4
 
With the increase binding of TRAIL to the death receptors and decreased levels of the 
anti-apoptotic proteins, these possibly mediated AGS to overcome its resistance to 
TRAIL-induced apoptosis.  
 
7.4. Combination of TRAIL and scopadulciol (11) enhanced degradation of β-
catenin in AGS. 
 Western blot analysis also showed that the combined treatment 11+TRAIL 
enhanced the degradation of β-catenin as early as 12 h (Figure 7.6a). Previous report had 
showed that combination of TRAIL with a Wnt inhibitor troglitazone had resulted in 
cleavage of β-catenin due to caspase activity.1 In contrast to their results, in the presence 
of the pan-caspase inhibitor z-VAD-fmk, the degradation of the β-catenin induced by the 
combined TRAIL and 11 was not prevented (Figure 7.6b). This result suggested that β-
catenin degradation by 11+TRAIL was not caspase-mediated. There is no yet clear 
evidence on the direct relationship of decreased β-catenin level to TRAIL-mediated 
apoptosis. Decrease in β-catenin level was observed when AGS was treated with TRAIL 
and natural compound sanguinarine.
7
 The increased apoptosis in Huh-7 cells by the 
combined treatment of troglitazone, a β-catenin/TCF transcription inhibitor, and TRAIL 
was attributed to the disassembly of the adherens junction caused by β -catenin 
degradation.
1
 Osteoprotogerin, which was reported to mediate resistance in colon cancer  
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cell, was shown to be a target gene of β-catenin.8, 9 However a study also showed that 
downregulation of β-catenin was found to decrease TRAIL-sensitivity by lowering the 
expression of DR4 and DR5 in colon cancer cell.
10
 In this study, we were able to observe 
caspase-independent β-catenin degradation by the combined 11+TRAIL which seems 
interesting, and warrant for further investigation. Since the function of Wnt/β-catenin 
signalling pathway mediates cancer cell growth and survival, β-catenin degradation may, 
at least partly, contribute to the action of TRAIL in inducing apoptosis.  
 
 
 
 
 
 
 
 
 
Figure 7.6. (a) Western blot analysis of β-catenin in AGS cells treated with 11 (200 nM) + 
TRAIL (100 ng/mL) for 12 h.  (b) Effect of z-VAD-fmk pretreatment on β-catenin level in 
AGS treated with 11 and TRAIL. Cells were pre-treated with z-VAD- fmk (50 µM) for 1 h 
and treated with 1 (200 nM) + TRAIL (100 ng/mL).  
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CHAPTER 8 
 
 
 
Summary and Conclusion 
  
 
 
The Wnt signal pathway plays a crucial role in many biological processes such as 
cell fate determination, proliferation and tissue maintenance. Abnormal activation of the 
Wnt signal can induce disease development, particularly cancer. Thus, targeting the Wnt 
signal offers a promising therapeutic strategy for the management of diseases. In our 
continued efforts to find for inhibitors from natural resources, we utilized a cell-based 
screen to identify potential plant sources of Wnt inhibitors. In this study, our objective is 
to isolate and identify the bioactive compounds from the “hit” plants. Furthermore, we 
aim to determine the putative mechanism through which the active compounds inhibit the 
Wnt signal. 
Using the STF/293 reporter cell which is a HEK293 cell line stably transfected 
with TOPflash reporter plasmid (TOP assay), we identified one Thai plant, Curcuma 
comosa (Zingiberaceae), and two Bangladeshi plants Scoparia dulcis (Plantaginaceae), 
and Azadirachta excelsa (Meliaceae) to possess inhibitory activity against TOP assay, 
thus, making them potential sources of Wnt inhibitors. The extracts of the identified 
plants were subjected to an activity-guided multistep separation using chromatographic 
techniques (silica gel chromatography, ODS, sephadex LH-20, Diaion HP-20, and HPLC), 
and recrystallization. The identity of the isolated compounds was established from their 
spectroscopic data (NMR, MS, CD, and specific rotation), and by comparison with those 
of literature values for the known compounds. Two new (1 and 2) and six (3-8) known 
diarylheptanoids, and two known sesquiterpenoids (9 and 10) were isolated from C. 
comosa.
1
 On the other hand, two scopadulan-type diterpenes (11 and 12), and two 
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triterpenes (13 and 14) were identified from S. dulcis. From A. excelsa, a new (15) and 
seven reported (16-22) trichillin-type limonoids were isolated. 
From the isolated compounds, compounds 1, 6-8 and 17-20 showed inhibitory 
activity against the TOP activity with IC50 < 10 µM. Compounds 1, 8, 17-19 did not 
significantly affect the FOP assay (negative reporter assay) which suggested that these 
compounds specifically inhibited the TOP activity.  Among these identified potent Wnt 
inhibitors, 17-19 showed the strongest TOP inhibitory activity with IC50 of 127, 300, and 
252 nM, respectively. Compound 18 decreased the viability of the Wnt-dependent cells 
HCT116 (IC50 239 nM), and AGS (IC50 161 nM) (Table 1). On the other hand, it did not 
affect the viability of SW480 and DLD1, also Wnt-dependent cancer cells.  
Compound 11 did not inhibit TCF/β-catenin transcription activity based on TOP 
assay using STF/293 cells but it exhibited cytotoxic activity against AGS cells, which has 
an active Wnt signal due to mutation in β-catenin. Western blot analysis showed that 11 
can induce degradation as well as inhibit nuclear accumulation of β-catenin. In the 
presence of either proteasome inhibitor MG132 or p53 transcriptional inhibitor pifithrin-α, 
the degradation induced by 11 was abrogated. We also observed that 11 decreased 
GSK3β level (Fig. 5b). These results indicated that β-catenin degradation by 11 in AGS is 
mediated by p53 and proteasome, and independent of GSK3β. Transient transfection of 
AGS cells with either TOP or FOP plasmid showed that 11 decreased TOP activity in 
without affecting the FOP activity. Also, western blot analysis showed that 11 
downregulated the level of the TCF/β-catenin target proteins c-myc, cyclin D1 and 
survivin. Results indicated that 11 inhibited the TCF/β-catenin transcription activity in 
AGS. 
On the other hand, when combined with TRAIL (tumor necrosis-related apoptosis 
inducing ligand), 11 resulted in increase in cytotoxic activity but inducing caspase-
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dependent apoptosis in AGS. The results showed that 11 had TRAIL-resistance 
overcoming activity. It sensitized AGS to TRAIL-induced apoptosis by increasing the 
level of DR4 and DR5, and downregulation of Bcl2. Furthermore, the 11+TRAIL also 
enhanced β-catenin degradation, which may, at least, partly contribute to the induction of 
apoptosis by TRAIL. 
In conclusion, using activity-guided isolation, ten compounds (1-10) were isolated 
from C. comosa, four (11-14) from S. dulcis, and eight (15-22) from A. excelsa. 
Compounds 1 and 2 are reported here as new diarylheptanoids, and 15 as new trichillin-
type limonoid. Compounds 18 showed inhibitory activity against TCF/β-catenin 
transcriptional activity in STF/293 reporter cells, and cytotoxicity against Wnt-dependent 
cancer cells AGS and HCT116. Compound 18 did not affect the level and localization of 
β-catenin in HCT116, but downregulated the level of the TCF/β-catenin target protein, c-
myc. Compound 11 attenuated the Wnt signal in AGS cells via p53- and proteasome-
mediated degradation of β-catenin, and inhibition of the accumulation of β-catenin in the 
nucleus. Furthermore, it showed TRAIL-resistance overcoming activity in AGS. The 
observed enhanced degradation of β-catenin by 11+TRAIL warrants for further 
investigation. 
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CHAPTER 9 
 
 
 
Regulation of neurogenesis by the 
 basic helix-loop-helix (bHLH) 
transcription factors 
 
 
 
9.1. Overview 
It is believed before that the ability of a brain to generate new neurons stops just 
after birth. However, studies showed that neural stem cells (NSCs) can also be found in 
the adult nervous system of all mammalian organisms, including humans.
1-3
 NSCs are 
multipotent cells that can differentiate to neurons, astrocytes and glial cells (Figure 9.1).
4
  
 
 
 
 
 
 
 
 
 
 
Neurogenesis in the adult nervous system is considered a significant discovery as 
it offers new strategies to develop treatment for neurodegenerative diseases. Some reports 
suggested that neurogenesis may replace lost neurons in Alzheimer’s disease5, and is 
involved in the formation of trace memories.
6
 However, the adult neurogenesis is being 
Figure 9.1. Differentiation of neural stem cells to neuron, 
astrocyte, and oligodendrocyte. 
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regulated by various factors such as the cell intrinsic programs and the environmental 
factors.
7
 Thus, the fate of NSCs can then be manipulated by regulating the pathway that is 
involved in neuronal fate specification. One of the factors that control neurogenesis is the 
basic helix-loop-helix genes (bHLH) which either repress or activate neurogenesis. The 
neurogenins (Ngn) are proneural genes that are key regulators of neurogeneis.
8
 In our 
study, we look for natural compounds that promote differentiation of NSCs to neurons by 
increasing the activity of Ngn2.  
 
9.2. The Basic helix-loop-helix transcription factors 
 The bHLH transcription factors are responsible for the control of the neural stem 
cell differentiation. They are categorized as either the repressor type or the activator type. 
The repressor type genes maintain NSCs as well as control gliogenesis while the activator 
type initiate neurogenesis (Figure 9.2).
9
  
 
 
 
 
 
 
 
 
 
 
  
Figure 9.2. Role of bHLH factors in neurogenesis. 
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The repressor type bHLH factors which includes the Hes (hairy and enhancer of 
split) family (Hes1, Hes3, and Hes5) inhibits transcription via two mechanisms: active 
and passive repression.
10
 In active repression, Hes factors form a homodimer and binds to 
the N box  (CACNAG). Then, a co-repressor TLE/Grg interacts with the dimer, and they 
actively repress transcription. In the passive repression, Hes1 forms a heterodimer with 
the bHLH activator E47, and inhibits transcriptional activation. On the other hand, some 
members of the neural bHLH or the activator type are Ngn family (Ngn1, Ngn2), Mash1 
and Math.
8
 They form a heterodimer with E47 and binds to the E box (CANNTG) to 
initiate transcription.   
 Moreover, neuronal differentiation is also dependent on the Notch pathway 
(Figure 9.3). Activation of the Notch pathway inhibits neuronal differentiation. It is said 
that expression of Ngn2 and Hes1 oscillates, thus maintaining a group of cells in 
undifferentiated state.
11
 When the level of Hes1 is low, Ngn2 level increases. Ngn2 
induces the expression of not only the proneural genes but also Notch ligands such as 
Dll1 which activates the Notch signal in the neighboring cells.
12
 When the Notch is 
activated, it induces the expression of the bHLH repressors. Thus, the Ngn2 level must 
then be sustained to induce the NSCs to undergo neuronal differentiation.
13 
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Figure 9.3. Regulatory pathways controlled by the activator and repressor bHLH. 
Figure adapted from Kageyama et al. (2005).
9
  
Neural stem cell Differentiating neuron 
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9.3. Reported compounds that induce neuronal differentiation 
 There are several compounds which are reported to induce neuronal 
differentiation. Most of these compounds were observed to increase the expression of 
some bHLH activators and decrease Hes1 expression (Figure 9.4). Docosahexanoic acid 
was reported to decrease the level of Hes1 while the level of a bHLH activator NeuroD 
was upregulated.
14
  Baicalin was also reported to increase the level of Ngn1, Ngn2, and 
NeuroD2.
15
 Retinoic acid induced neuronal differentiation by increasing NeuroD.
16
 On 
the other hand, ginsenosides Rg5 induced neuronal differentiation by increasing Ca
2+
-
influx via voltage-gated channel resulted in increased bHLH activator expression.
17
 Our 
laboratory has also reported Ngn2 activators from a plant Butea superba. Using our 
constructed Ngn2 promoter assay, we were able to identify 3’-methoxydaidzein to 
enhance Ngn2 promoter activity. Moreover, it also promoted neurite outgrowth in C17.2 
and upregulated the mRNA expression of Ngn2, Ngn1 and NeuroD2.
18
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CHAPTER 10 
 
 
 
Ngn2 Promoter Assay Protocol 
 
 
10.1. Cell-based luciferase assay system 
 The Ngn2 promoter activity was evaluated using our previously reported cell-based 
luciferase assay system.
1
 The assay system utilized C3H10T1/2 cells stably transfected 
with pGL4.20 vector (Promega) containing Ngn2 promoter inserted upstream of the 
luciferase gene (Figure 10.1). The activation of the Ngn2 promoter leads to the 
transcription of the luciferase gene. This enzyme catalyzes the oxidative conversion of 
luciferin to oxyluciferin. In this chemical transformation, light also is being produced in 
which luminescence is measured and the relative activity is calculated. 
 
 
 
 
 
 
 
 
 
10.2. Methods 
10.2.1. Ngn2 reporter assay 
The Ngn2 promoter activity assay was conducted using the methods described 
previously.
1
 C3H10T1/2 cells stably transfected with a plasmid containing an Ngn2 
promoter were seeded in 96-well plate at a density of 1 x 10
4
 cells/well. After 24 h 
Figure 10.1. Ngn2 reporter plasmid. 
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incubation, different concentrations of compounds were added and incubated for 24 h. 
Then, cells were lysed with Glo Lysis Buffer. Luciferase activity was measured using 
Bright-Glo Luciferase Assay System (Promega) according to manufacturer’s 
recommendations. Relative Ngn2 promoter activity of the control (50% EtOH only) is 
defined as 100% and the activity of the other treatments were calculated accordingly.  
 
                               
                               
                       
       
 
10.2.2. Neuronal differentiation activity 
 Briefly, cells at a density of 2 x 10
4
 cells/well in proliferation medium [DMEM 
(high glucose with L-Glutamine); 5 µg/mL insulin; 10 ng/mL EGF; 50 µg/mL transferrin; 
10 ng/mL biotin and 30 nM Na2SeO3] were seeded in 24 well plate with a poly-L-
lysine/laminine-coated coverslip in each well. The cells were incubated for 24 h at 37 °C. 
After 24 h, the medium was removed and the cells were washed with DMEM only. Then 
the cells were treated with the samples prepared in differentiation medium [NeuroCult 
Basal Medium (mouse) with 10% NSC differentiation supplements (mouse)] for 4 d. 
After the treatment, the medium was removed and then washed with 500 µL PBS twice 
for 5 min. Then, the cells were fixed with 500 µL 4% paraformaldehyde for 30 min.  The 
cells were then washed with 500 µL PBS twice for 5 mins, and added with a blocking 
buffer (1% BSA+1% Triton-X in PBS) for 1 h. After blocking, the cells were washed 
with 300 µL PBS twice for 5 min. Combined primary antibodies (200 µL) [mouse anti-
TUJ1 (1:400) + mouse anti-GFAP (1:400)] was added to the cells, and were incubated 
overnight at 4°C. Then, the primary antibodies were removed, and the cells were washed 
with 300 µL PBS twice for 5 min. After washing, the cells were incubated with the 
secondary antibodies [anti-rabbit Alexa Fluor 555 (1:500) + anti-goat Alexa Fluor 488 
101 
 
(1:500) with 250 µg/mL RNAse] in the dark for 1 h. Then, the secondary antibodies were 
removed, and the cells were washed with 300 µL PBS twice for 5 min. The cells were 
then counterstained with 200 µL TO-PRO (1µM) for 1 h. After counterstaining, the 
coverslips were removed from the 24-well plate and mounted in glass slide using a 
ProLong
® 
Gold Antifade Reagent Special Packaging. The cells were viewed using 
Olympus FV500, and the cells were analyzed using ImageJ.
2
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CHAPTER 11 
 
 
 
Phenolic compounds from Oroxylum indicum that 
activate Ngn2 promoter activity 
 
 
 
11.1. Plant Description 
 Oroxylum indicum Linn., which belongs to family Bignoniaceae, is a known 
medicinal plant that grows in India, Japan, and Malaysia. Locals use it as treatment for 
common illnesses such as diarrhea, fever and jaundice.
1
 Pharmacological studies showed 
that O. indicum contains antimicrobial,
2
 antiinflammatory,
2
 antimutagenic
3
 and 
antioxidant properties.
4
 Moreover, the falvanoid baicalein was isolated from O. indicum, 
and the compound showed antiproliferative activity against cancer cell.
5
 The bark sample 
of O. indicum used in this study was collected from Bangladesh. Its MeOH extract was 
screened by the previous student, and its Ngn2 promoter activity was 192% at 100 
µg/mL.6 Liquid-liquid partition of its MeOH extract showed that its hexane extract 
showed the strongest activity with 250% at 50 µg/mL. It was followed by the EtOAc 
fraction (200%), and then BuOH fraction (150%). The water-soluble component of the 
extracts did not show induction of the Ngn2 promoter activity.  
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Figure 11.1 Ngn2 promoter activity of O. indicum hexane, 
EtOAc, BuOH and aqueous fractions. 
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11.2. Isolation of the constituents 
Figure 11.2 shows the isolation scheme of O. indicum. The dried bark of O. 
indicum (336 g) was extracted in MeOH to give the crude extract (13.9 g). The extract 
was re-suspended in 10% MeOH (300 mL) and partitioned between n-hexane, EtOAc, 
and n-BuOH (300 mL x 3). The hexane fraction (3.9 g) was then subjected to silica gel 
column chromatography (φ25 x 330 mm) with CHCl3:MeOH (0:1-1:1) to give fractions 
nine fractions (1A-1I). Fraction 1C (40.3 mg) was subjected to ODS column 
chromatography (φ15 x 250 mm) and eluted with H2O:MeOH (1:1-0:1) to yield 23 (13.4 
mg). Fraction 1E ((φ25 x 280 mm) was subjected to silica gel column chromatography 
(φ25 x 280 mm) to afford 23 (10.8 mg), 24 (6.8 mg), 25 (13 mg) and 26 (58.1 mg). 
Fraction 1F (1161.1 mg) was subjected to ODS column chromatography (φ20 x 270 mm) 
using H2O:MeOH (1:1-0:1) as the eluent to yield ten fractions (6A-6J). The methanol-
soluble of fraction 6E (11.0 mg) was then further purified by HPLC [Cosmosil 5C18-AR-
II; φ10 x 250 mm; 45% MeCN] to obtain 27 (1.4 mg). The BuOH fraction (2.8 g) was 
then subjected to ODS column chromatography (φ30 x 270 mm) with H2O:MeOH (9:1-
1:1) and yielded fractions 8A-8I. Fraction 8D (92 mg) was subjected to HPLC [Cosmosil 
5C18-AR-II; φ10 x 250 mm; 30% MeOH] to afford 28 (tR=16 min; 30.8 mg). Fraction 8G 
(30.2 mg) was further purified by ODS column chromatography (φ230 x 120 mm) using 
50% MeOH to yield compound 29 (9.0 mg). 
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Figure 11.2. Isolation scheme of O. indicum 
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11.3. Characterization of the isolated compounds 
 Activity-guided multistep separation using chromatographic techniques (silica, 
ODS and HPLC) led to the isolation of six known flavonoids (23-28), and a phenyl ethyl 
glycoside (29). Their structures were identified by comparing their spectral values with 
those in literatures. 
Oroxylin A (23)
7
 
1
H and 
13
C NMR see Table 11.1; ESI-MS: m/z 284 [M+H]
+ 
   
Chrysin (24)
8
 
1
H and 
13
C NMR see Table 11.1; ESI-MS: m/z 253 [M+H]
+ 
Hispidulin (25)
9
 
1
H and 
13
C NMR see Table 11.1; ESI-MS m/z 270 [M+H]
+ 
Baicalein (26)
10
 
1
H and 
13
C NMR see Table 11.2; ESIMS: m/z 269 [M+H]
+ 
Apigenin (27)
11
 
1
H and 
13
C NMR see Table 11.2; ESIMS: m/z 269 [M+H]
+ 
Baicalin (28)
12
 
1
H and 
13
C NMR see Table 11.2; ESIMS: m/z 445 [M-H]
+ 
Verbascoside (29)
13
  
1
H and 
13
C NMR see Table 11.3; ESIMS: m/z 623 [M-H]
- 
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Table 11.1. NMR spectroscopic data of compounds 23, 24 and 25 (DMSO-d6, 400 MHz). 
Position 
23 24 25 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 1H (δ, ppm; J, Hz) 1H (δ, ppm; J, Hz) 
1     
2  163.2   
3 5.61 (1H, s) 104.8 6.96 (1H, s) 6.58 (1H, s) 
4  182.2   
5  152.6   
6    94.4 6.21 (1H, d, 2.4)  
7  157.8   
8 6.96 (1H, s) 130.8 6.52 (1H, d, 2.4) 6.77 (1H, s) 
9  152.7   
10  104.4   
1’  131.5   
2’ 8.06 (1H, d, 6.8) 126.4 8.05-8.07 (1H, m) 7.92 (1H, d, 8.6) 
3’ 7.62-7.55 (1H, m) 129.1 7.54-7.63 (1H, m) 6.91 (1H, d, 8.6) 
4’ 7.62-7.55 (1H, m) 132.0 7.54-7.63 (1H, m)  
5’ 7.62-7.55 (1H, m) 129.1 7.54-7.63 (1H, m) 6.91 (1H, d, 8.6) 
6’ 8.06 (1H, d, 6.8) 126.4 8.05-8.07 (1H, m) 7.92 (1H, d, 8.6) 
6-OMe 3.75 (3H, s)   59.9  3.74 (3H, s) 
5-OH 12.92 (1H, s)  12.82 (1H,s) 13.07 (1H, s) 
7-OH    10.70 (1H, s) 
4’-OH    10.35 (1H, s) 
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Table 11.2. NMR spectroscopic data of compounds 26, 27, and 28 (DMSO-d6). 
Position 
26 (400 MHz) 27 (400 MHz) 28 (600 MHz) 
1H (δ, ppm; J, Hz) 1H (δ, ppm; J, Hz) 1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1     
2    163.68 
3 6.92 (1H, s) 6.55 (1H, s) 7.03 (1H, s) 106.28 
4    182.78 
5    146.81 
6  6.15 (1H, d, 2)  130.02 
7    154.94 
8 6.62 (1H, d, 2.4) 6.40 (1H, d, 2) 6.98 (1H, s)   94.49 
9    149.40 
10    104.88 
1’    131.02 
2’ 8.03 (1H, dd, 8.1,1.1) 7.82 (1H, d, 8.8) 8.06 (1H, d, 8.4) 126.58 
3’ 7.58 (1H, m) 6.90 (1H, d, 8.8) 7.58 (1H, m) 129.39 
4’ 7.58 (1H, m)  7.58 (1H, m) 132.23 
5’ 7.58 (1H, m) 6.90 (1H, d, 8.8) 7.58 (1H, m) 129.39 
6’ 8.03 (1H, dd, 8.1, 1.1) 7.82 (1H, d, 8.8) 8.06 (1H, d, 8.4) 126.58 
5-OH 12.65 (1H, s)    
6-OH 8.80 (1H, s)    
7-OH 10.56 (1H, s)    
4’-OH     
Glucoronide     
1”   5.02 (1H, d, 7.2) 100.92 
2”   3.22 (1H, m)   73.15 
3”   3.22 (1H, m)   74.49 
4”   3.22 (1H, m)   72.12 
5”   3.64 (1H, d, 9.6)   76.02 
6”    171.32 
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Table 11.3. NMR spectroscopic data of compound 29 (in CD3OD, 600 MHz). 
Position 
29 
1H (δ, ppm; J, Hz) 13C (δ, ppm) 
1  131.5 
2 6.64 (1H, d, 1.8) 116.3 
3  144.7 
4  146.1 
5 6.62 (1H, d, 8.1) 117.1 
6 6.52 (1H, dd, 8.1, 1.8) 121.3 
α 4.00 (1H, m) 
3.67 (1H, m) 
  72.4 
β 2.75 (2H, m) 36.6 
Glucose   
1’ 4.33 (1H, d, 7.2) 104.2 
2’ 3.57 (1H, m)   76.2 
3’ 3.50 (1H, m)   81.2 
4’ 4.85 (1H, m)   70.4 
5’ 3.65 (1H, m)   76.1 
6’ 3.87 (1H, m) 
3.69 (1H, m) 
  62.4 
Caffeoyl   
1’’  127.7 
2’’ 7.01 (1H, d, 2.1) 115.2 
3’’  148.0 
4’’  149.8 
5’’ 6.73 (1H, d, 8.4) 116.5 
6’’ 6.23 (1H, dd, 8.4, 2.1) 123.2 
α’’ 6.23 (1H, d, 15.6) 114.7 
β’’ 7.55 (1H, d, 15.6) 146.8 
C=O  168.3 
Rhamnose   
1’’’ 5.14 (1H, d, 1.2) 103.0 
2’’’ 3.77 (1H, t, 18.6)   72.3 
3’’’ 3.34 (1H, m)   72.1 
4’’’ 3.25 (1H, m)   73.8 
5’’’ 3.65 (1H, m)   70.6 
6’’’ 1.04 (3H, d, 6)   18.4 
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11.4. Ngn2 promoter activity of compounds 23-28 
 The Ngn2 promoter activity of compounds 23-28 were determined based on 
concentration- and time-dependence. Compound 29 was not subjected to further assay as 
it was isolated from an inactive fraction. Result showed that all compounds were dose-
dependent, that is, high activity is observed at high concentration (Figure 11.3). However, 
it is observed that at high concentration, their activities reached a plateau. Oroxylin A 
(23) and hispidulin (25) reached their highest activity at 10 µM while chrysin (24) at 15 
µM. Oroxylin A (23) increased Ngn2 promoter activity by 2.6 folds while hispidulin (25)  
by 2.4 folds. Chrysin (24) exhibited 2.4-fold increase in activity. Baicalein (26) and 
apigenin (27) also induced Ngn2 promoter activity by 201% and 170%, respectively at 15 
µM. On the other hand, Baicalin (28) showed the weakest activity as their highest activity 
of 181% and 136%, respectively, was observed at 200 µM. In the time-dependent activity, 
all compounds showed a time-dependent biphasic response (Figure 11.4). Their highest 
activity was observed after 24 h, but decreased after 48 h treatment. 
 
11.5. Neuronal differentiation activity of 23 
 The neuronal differentiation activity of 23 was then determined using the 
multipotent cell line, MEB5 cells. Figure 11.5 shows MEB5 cells with or without 23 
stained with TUJ1 (neuron marker), GFAP (astrocyte marker), and TO-PRO (nuclues 
marker).  Immunostaining revealed that more neurons with a neurite length of about 200 
μm were observed in MEB5 cells treated with as compared to control. The results 
suggested that 23 resulted in neuronal population with longer neurites. This means that 23 
had neuronal differentiation activity.  Compound 23 had been reported to induce adult 
neurogenesis in the hippocampal dentate gyrus region of mice.
14
 Possibly, induction of 
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the Ngn2 promoter by 23 may have participated in the stimulation of the neuronal 
differentiation. 
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Figure 11.3. Concentration-dependent Ngn2 promoter activity of compounds 23-29. 
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Figure 11.4. Time-dependent Ngn2 promoter activity of compounds 23-29. 
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CHAPTER 12 
 
 
 
Ngn2 Promoter activity of Longistylin C  
isolated from Cajanus cajan 
 
 
 
12.1. Plant Description 
 Cajanus cajan belongs to the family Fabaceae. It is reported to have antioxidant 
and antiinflammatory,
1
 antiplasmoidal,
2
 and neuroprotective
3 
properties. Some of the 
isolated compounds reported from this plant are cajanol, longistylin A and longistylin C.
2
 
In this study, the leaves were used and the sample was collected from Bangladesh. During 
the screening activity, the MeOH extract of C. cajan enhanced Ngn2 promoter activity by 
200% at 100 µg/mL. After removal of the chlorophyll content by Diaion HP20, fraction 
1A was observed to have similar induction activity and was subjected to further isolation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.1. Ngn2 promoter activity of the 1 series. 
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12.2. Isolation of the constituents 
Figure 12.2 shows the isolation scheme of C. cajan. The dried leaves of C. cajan 
(145 g) were extracted in MeOH and yielded 7.6 g of crude MeOH extract. The 
chlorophyll content was removed using Diaion HP20 column chromatography (φ50 x 270 
mm) using MeOH:Acetone (1:0-0:1) to give fractions 1A-1C. Fraction 1A (6.7 g) eluted 
using 100% MeOH was re-suspended in 10% MeOH (300 mL) and partitioned between 
n-hexane, EtOAc, and n-BuOH (300 mL x 3) to afford the hexane extract (1.9 g), EtOAc 
extract (0.6 g), BuOH extract (2.0 g) and the water-soluble extract (2.3 g). The combined 
fractions of the hexane and EtOAc layers were subjected to silica column 
chromatography (φ50 x 240 mm) using CHCl3:MeOH (1:0-0:0.1% TFA in MeOH) to 
give eleven fractions (2A-2K). Fraction 2D was then further purified by HPLC [Cosmosil 
5C18-AR-II; φ10 x 250 mm; 80% MeOH to afford fractions 3A-3D in which 3B was 
identified as 30 (tR=35.4 min 3.1 mg). Fraction 3A was again subjected to HPLC 
[Phenomenex Luna 5u Phenyl-Hexyl; φ10 x 250 mm; 80% MeOH] and give 31 (tR=31 
min 7.6 mg).  
 
12.3. Characterization of the isolated compounds 
 Activity-guided multistep separation using chromatographic techniques (silica, 
ODS and HPLC) led to the isolation of two known compounds (31-32). Their structures 
were identified by comparing their spectral values with those in literatures. 
Longistylin C (31)
2
 
1
H and 
13
C NMR see Table 12.1; ESI-MS: m/z 293 [M-H]
- 
   
Pinostrobin (32)
4
 
1
H and 
13
C NMR see Table 12.2; ESI-MS: m/z 269 [M-H]
- 
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Figure 12.2. Isolation scheme of C. cajan. 
 
120 
 
 
 
 
 
 
Table 12.1. NMR spectroscopic data of compound 30 (in CDCl3). 
Position 
30 
1H (δ, ppm; J, Hz) 
(400 MHz)  
13C (δ, ppm) 
(150 MHz) 
1  137.3 
2  115.0 
3  158.1 
4 6.62 (1H, d, 1.6) 101.6 
5  155.5 
6 6.64 (1H, d, 1.6) 107.0 
7 6.98 (1H, d, 16) 128.4 
8 7.03 (1H, d, 16) 128.4 
9  136.6 
10 7.48 (1H, m) 126.5 
11 7.33 (1H, m) 128.7 
12 7.33 (1H, m) 127.6 
13 7.33 (1H, m) 128.7 
14 7.48 (1H, m) 126.5 
15 3.39 (2H, d, 4.4)   22.4 
16 5.22 (1H, t, 7.2) 121.8 
17  134.5 
18 1.80 (3H, s)   17.9 
19 1.72 (3H, s)   25.8 
3-OCH3 3.87 (3H, s)   55.8 
 
 
 
 
 
 
Table 12.1. NMR spectroscopic data of compound 31 (in CDCl3). 
Position 
31 
1H (δ, ppm; J, Hz) 
(400 MHz)  
13C (δ, ppm) 
(150 MHz) 
1   
2 5.41 (1H, dd, 12, 2.8)   79.2 
3 3.07 (1H, dd, 17.2, 12.8) 
2.81 (1H, dd, 17, 3) 
  43.4 
4  195.8 
5  162.8 
6 6.06 (1H, d, 3.2)   95.1 
7  168.0 
8 6.06 (1H, d, 3.2)   94.2 
9  164.1 
10  103.1 
1’  138.4 
2’ 7.40 (1H, m) 126.1 
3’ 7.40 (1H, m) 126.1 
4’ 7.40 (1H, m) 128.9 
5’ 7.40 (1H, m) 126.1 
6’ 7.40 (1H, m) 126.1 
5-OH 12.00 (1H, brs)  
7-OCH3 3.80 (3H, s)   55.7 
30 31 
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12.4. Ngn2 promoter activity of longistylin C (30) 
 Figure 12.2 shows the Ngn2 promoter activity of longisylin C (30). It is observed 
that it enhanced the Ngn2 promoter activity in a dose-dependent manner. However, it was 
also shown that at 10 µM, it started to reach its highest activity (180%), and its activity 
became almost unchanged. The result suggested that longistylin C may be a potent 
compound that can enhance neuronal differentiation. On the other hand, pinostrobin (31) 
was inactive. 
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Figure 12.3. Dose-dependent Ngn2 promoter activity of 30. 
122 
 
References 
 
1. Lai, Y.-S.; Hsu, W.-H.; Huang, J.-J.; Wu, S.-C., Antioxidant and anti-
inflammatory effects of pigeon pea (Cajanus cajan L.) extracts on hydrogen 
peroxide- and lipopolysaccharide-treated RAW264.7 macrophages. Food Func. 
2012, 3, 1294-1301. 
 
2. Duker-Eshun, G.; Jaroszewski, J. W.; Asomaning, W. A.; Oppong-Boachie, F.; 
Brøgger Christensen, S., Antiplasmodial constituents of Cajanus cajan. Phytother. 
Res. 2004, 18, 128-30. 
 
3. Ruan, C. J.; Si, J. Y.; Zhang, L.; Chen, D. H.; Du, G. H.; Su, L., Protective effect 
of stilbenes containing extract-fraction from Cajanus cajan L. on Abeta(25-35)-
induced cognitive deficits in mice. Neurosci. Lett. 2009, 467, 159-63. 
 
4. Ching, A. Y. L.; Wah, T. S.; Sukari, M. A.; Lian, G. E. C.; Rahmani, M.; Khalid, 
K., Characterization of flavonoid derivatives from Boesenbergia rotunda (L.) The 
Malaysian Journal of Analytical Sciences 2007, 11, 154-159. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
CHAPTER 13 
 
 
 
Summary and Conclusion 
  
 
 
Differentiation of neural stem cells (NSCs) is controlled by many basic helix-loop-helix 
(bHLH) factors. Ngn2, a bHLH activator promotes the differentiation of NSCs to neurons. However, 
in undifferentiated cells its expression is inhibited by the repressor type of bHLH such as Hes1. 
Neuronal differentiation occurs when the level of proneural gene Ngn2 is sustained.  In this study, we 
aim to discover natural compounds that would enhance neuronal differentiation of NSCs by enhancing 
the activity of Ngn2.  
The Ngn2 promoter activity was evaluated using a cell-based luciferase assay system in which 
C3H10T1//2 were stably transfected with a plasmid containing an Ngn2 promoter. Using this assay, we 
identified KKB085 Oroxylum. indicum and KKB143 Cajanus cajan to induce Ngn2 promoter activity. 
Activity-guided multistep separation using chromatographic techniques led to the isolation of seven 
known flavonoids (23-28), and one phenyl ethyl glycoside (29) from O. indicum; and a stilbene (30) 
and one flavonoid (31) from C. cajan. Compounds 23-26 and 31 showed the highest Ngn2 promoter 
activity. As compared with control, compound 23 increased the number of neurons with longer neurite 
using MEB5 cells.  The results suggested that 23 could induce neuronal differentiation by increasing 
the Ngn2 promoter activity. 
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APPENDIX I 
 
 
 
Screening of the KKB Plant Extracts 
(TOP Assay) 
 
 
 
 
 
 
 
0
100
200
300
400
500
10 100 10 100 10 100 10 100 10 100 10 100
KKB254 KKB255 KKB259 KKB262 KKB263 KKB264
(%
) 
µg/mL 
TOP Viability
0
100
200
300
400
500
10 100 10 100 10 100 10 100 10 100 10 100 10 100
KKB265 KKB266 KKB269 KKB270 KKB271 KKB272 KKB273
(%
) 
µg/mL 
TOP Viability
128 
 
 
 
 
 
 
 
 
0
100
200
300
400
500
10 100 10 100 10 100 10 100 10 100 10 100 10 100
KKB274 KKB275 KKB278 KKB279 KKB280 KKB281 KKB282
(%
) 
µg/mL 
TOP Viability
0
100
200
300
400
500
10 100 10 100 10 100 10 100 10 100 10 100 10 100
KKB283 KKB284 KKB285 KKB286 KKB295 KKB296 KKB297
(%
) 
µg/mL 
TOP Viability
0
100
200
300
400
500
10 100 10 100 10 100 10 100 10 100 10 100 10 100
KKB298 KKB299 KKB300 KKB301 KKB302 KKB303 KKB304
(%
) 
µg/mL 
TOP Viability
129 
 
APPENDIX II 
 
 
 
List of Screened KKB Plant Extracts 
(TOP Assay) 
 
KKB NO. SCIENTIFIC NAME FAMILY 
PLANT PART 
USED 
KKB0254 Xanthium strumarium Asteraceae Stem 
KKB0255 Xanthium strumarium Asteraceae Leaves 
KKB0259 Madhuca longifolia Sapotaceae Leaves 
KKB0262 Solanum surattense Solanaceae Fruit 
KKB0263 Solanum surattense Solanaceae Leaves 
KKB0264 Phyllanthus reticulatus Phyllanthaceae Stem 
KKB0265 Odina wodier Roxb. Anacardiaceae Bark 
KKB0266 Sansevieria sp. Ruscaceae Whole plant 
KKB0269 Acacia mangium Fabaceae  Leaves 
KKB0270 Tabernaemontana divaricata Apocynaceae Aerial parts 
KKB0271 Jasminum spp.  Oleaceae Aerial parts 
KKB0272 Randia spp.  Rubiaceae Aerial parts 
KKB0273 Flacourtia spp.  Flacourtiaceae Aerial parts 
KKB0274 Syzygium cumini Myrtaceae Leaves 
KKB0275 Suregada multiflora Euphorbiaceae Aerial parts 
KKB0278 Croton spp.  Euphorbiaceae Leaves 
KKB0279 Semecarpus anacardium Anacardiaceae Leaves 
KKB0280 Syzygium fruticosum Myrtaceae Leaves 
KKB0281 Hollarhena spp.  Apocynaceae Leaves 
KKB0282 Mucuna spp.  Fabaceae Leaves 
KKB0283 Bridelia spp.  Euphorbiaceae Leaves 
KKB0284 Microcos paniculata Malvaceae Aerial parts 
KKB0285 Terminalia bellirica Combretaceae Leaves 
KKB0286 Dalbergia spp. Fabaceae Aerial parts 
KKB0295 Evolvulus nummularias Convolvulaceae Aerial parts 
KKB0296 Leea indica Leeaceae Aerial parts 
KKB0297 Phyla nudiflora Verbanaceae Aerial parts 
KKB0298 Hibiscus sabdariffa Malvaceae Aerial parts 
KKB0299 
Ecbolium linneanum   
Justicia ecbolia 
Acanthaceae Aerial parts 
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APPENDIX III 
 
 
 
Screening of the KKP Plant Extracts 
(TOP Assay) 
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APPENDIX IV 
 
 
 
List of Screened KKP Plant Extracts  
(TOP Assay) 
 
KKB NO. SCIENTIFIC NAME FAMILY PLANT PART USED 
KKP308 Aegle marmelos Rutaceae leaf 
KKP309 Citrus maxima Rutaceae peel 
KKP310 Clausena lansium Rutaceae leaf 
KKP311 Clausena harmandiana Rutaceae leaf 
KKP312 Murraya paniculata Rutaceae leaf 
KKP313 Toddalia aculeata Rutaceae leaf 
KKP314 Picrasma javanica Simaroubaceae leaf 
KKP315 Eurycoma longifolia Simaroubaceae root 
KKP316 Canarium album Burseraceae leaf 
KKP317 Canarium album Burseraceae fruit 
KKP318 Alpinia oxymitra Zingiberaceae rhizome 
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APPENDIX V 
 
 
 
Screening of the KKB Plant Extracts 
(Ngn2 Promoter Activity) 
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APPENDIX VI 
 
 
 
List of Screened KKB Plant Extracts 
(Ngn2 Promoter) Activity 
 
KKB NO. SCIENTIFIC NAME FAMILY 
PLANT PART 
USED 
KKB0124 
KKB0125 
KKB0126 
KKB0127 
KKB0128 
KKB0129 
KKB0130 
KKB0131 
KKB0132 
KKB0133 
KKB0134 
KKB0135 
KKB0136 
KKB0137 
KKB0138 
KKB0139 
KKB0140 
KKB0141 
KKB0142 
KKB0143 
KKB0144 
KKB0145 
KKB0146 
KKB0147 
KKB0148 
KKB0149 
KKB0150 
KKB0151 
KKB0152 
KKB0153 
KKB0154 
KKB0155 
KKB0156 
KKB0157 
KKB0158 
KKB0159 
Ipomoea sp. 
Wikstroemia indica Meisson.   
Sida acuta Burm.   
Synedrella nodifloea Gaertn. 
Lygodium flexuoaum Sw. 
Desmodium triquetrum Dc. 
Croton lobetus Linn. 
Elephantopous scaber L. 
Urena lobata Linn. 
Melastoma malabathricum L. 
Ziziphus oenoplea (L.) Mill.  
Thysanolaena maxima (Rox) O. Kulze. 
Solanum indicum 
Spilanthes acemella 
Eupatorium odoratum 
Microcos paniculata 
Lantana camara 
Achyranthes aspera Linn. 
Ocimum sanctum 
Cajanuus cajan Linn. 
Allamanda spp. 
Anisomeles indica 
Hibiscus surattensis L. 
Ipomea pescapra R. Br  
Tecoma stans (L.) Juss  
Clinogyne dichotoma Salisb 
Flemingia congesta 
Ardisia humilis 
Ecbolium linnaenum 
Polygonum lanatum 
Costus specious 
Sonneratia apetala 
Gendarussa vulgaris 
Nymphea nouchali 
Sida rhombifolia Linn. 
Bacopa monnieri 
Convolvulaceae  
Thymelaeaceae  
Malvaceae  
Compositae 
Schizaeceae 
Papilonaceae  
Euphorbiaceae  
Compositae 
Malvaceae 
Melastomaceae 
Rhamnaceae 
Poaceae 
Malvaceae 
Compositae 
Compositae 
Tiliaceae 
Verbenaceae 
Amaranthaceae 
Labiatae 
Fabaceae 
Apocynaceae 
Lamiaceae 
Malvaceae 
Convolvulaceae 
Bignoniaceae 
Marantaceae 
Papilionaceae 
Myrsinaceae 
Acanthaceae 
Polygonaceae 
Costaceae 
Sonneratiaceae 
Acanthaceae 
Nymphaeaceae 
Malvaceae 
Scrophulariaceae 
Aerial  
Aerial 
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Leaves 
Aerial  
Aerial  
Aerial  
Aerial  
Aerial  
Leaves with small branches 
Leaves 
Leaves 
Leaves 
Leaves 
Leaves 
Fruit stalk 
Leaves 
Roots 
Aerial  
Whole plants 
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KKB0160 
KKB0169 
KKB0170 
KKB0171 
KKB0172 
KKB0173 
KKB0174 
KKB0175 
KKB0176 
KKB0178 
KKB0179 
KKB0180 
KKB0181 
KKB0183 
KKB0185 
KKB0187 
KKB0188 
KKB0189 
KKB0190 
KKB0192 
KKB0193 
KKB0194 
KKB0195 
KKB0196 
KKB0197 
KKB0198 
KKB0200 
KKB0204 
KKB0206 
KKB0212 
KKB0217 
KKB0219 
KKB0220 
 
Rumex maritimus 
Azadirachta indica 
Aphanamixis polystachya 
Aphanamixis polystachya 
Tagetes erecta 
Tagetes erecta 
Ipomoea mauritiana 
Ipomoea mauritiana 
Argemone mexicana 
Manihot esculenta 
Manihot esculenta 
Coccinea cordifolia 
Hibiscus feculneus 
Ficus benghalensis 
Datura stramonium 
Cyperus rotundus 
Terminalia arjuna 
Terminalia arjuna 
Sida cordifolia 
Achyramthes aspera 
Achyramthes aspera 
Datura metel 
Datura metel 
Datura metel 
Acalypha indica 
Ficus religiosa 
Ficus religiosa 
Solanum nigrum 
Eugenia jambolana 
Smilax zeylanica 
Withania somnifera 
Leucas aspera 
Adhatoda vasica 
 
Polygonaceae 
Meliaceae 
Meliaceae 
Meliaceae 
Compositae 
Compositae 
Convolvulaceae 
Convolvulaceae 
Papaveraceae 
Euphorbiaceae 
Euphorbiaceae 
Cucurbitaceae 
Malvaceae 
Moraceae 
solanaceae 
Cyperaceae 
Combretaceae 
Combretaceae 
Malvaceae 
Amaranthaceae 
Amaranthaceae 
Solanaceae 
Solanaceae 
Solanaceae 
Euphorbiaceae 
Moraceae 
Moraceae 
Solanaceae 
Myrtaceae 
Liliaceae 
Solanaceae 
Lamiaceae 
Acanthaceae 
 
Aerial  
Leaves 
Stem 
Leaves 
Stem 
Leaves 
Stem 
Fruit 
Stem 
Stem 
Leaves 
Stem 
Stem 
Root bulb 
Fruit 
Leaves 
Fruit 
Bark 
Leaves 
Leaves 
Stem 
Leaves 
Stem 
Roots 
Stem 
Leaves 
Bark 
Leaves 
Seed 
Stem 
Leaves 
Stem 
Stem 
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APPENDIX VII 
 
 
 
Screening of the KKP Plant Extracts 
(Ngn2 Promoter Activity) 
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APPENDIX VIII 
 
 
 
List of Screened KKP Plant Extracts 
(Ngn2 Promoter Activity) 
 
 
KKP NO. SCIENTIFIC NAME FAMILY 
PLANT PART 
USED 
 
KKP292 Bryophyllum pinnatum Crassulaceae leaf 
KKP293 Artocarpus integra Moraceae root 
KKP294 Streblus asper Moraceae leaf 
KKP297 Millingtonia hortensis Bignoniaceae branch 
KKP298 Millingtonia hortensis Bignoniaceae leaf 
KKP299 Bidens pilosa Asterceae whole 
KKP300 Celastrus paniculata Celastraceae leaf 
KKP301 Lophopetalum wallichii Celastraceae leaf 
KKP302 Rheo discolor Commelinaceae whole 
KKP303 Murdannia loriformis Commelinaceae whole 
KKP304 Merremia umbellata Convulvulaceae leaf 
KKP305 Santalum album Santalaceae wood 
KKP306 Vitis vinifera Vitaceae leaf 
KKP307 Acronychia laurifolia Rutaceae leaf 
KKP308 Aegle marmelos Rutaceae leaf 
KKP309 Citrus maxima Rutaceae peel 
KKP310 Clausena lansium Rutaceae leaf 
KKP311 Clausena harmandiana Rutaceae leaf 
KKP312 Murraya paniculata Rutaceae leaf 
KKP313 Toddalia aculeata Rutaceae leaf 
KKP314 Picrasma javanica Simaroubaceae leaf 
KKP315 Eurycoma longifolia Simaroubaceae root 
KKP316 Canarium album Burseraceae leaf 
KKP317 Canarium album Burseraceae fruit 
KKP318 Alpinia oxymitra Zingiberaceae rhizome 
KKP319 Amomum villosum Zingiberaceae rhizome 
KKP320 Aglaia odorata Meliaceae leaf 
 
 
 
138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
139 
 
APPENDIX IX 
 
 
 
Characteristics of the New Compounds 
 
Compound 1. Colorless solid; [α]26D -9.9 (c 0.5 MeOH); positive HRESIMS [M+Na]
+
 
m/z 381.1634 (calcd. for C21H26O5Na 381.1678, Δ -4.4 mmu); UV λmax (MeOH) nm (log 
ε) 278 (3.6) and 223 (4.2) IR νmax 3354, 2924, 1706, 1514, and 1242; 
1
H NMR (CD3OD, 
600 MHz) and 
13
C NMR (CD3OD, 150 MHz), see Table 3.1. 
Compound 2. Colorless solid; positive HRESIMS [M+Na]
+
 m/z 399.1762 (calcd. for 
C21H28O6Na 399.1784, Δ -2.1 mmu; 
1
H NMR (CDCl3, 600 MHz) and 
13
C NMR (CDCl3, 
150 MHz), see Table 3.1. 
Compound 15. Colorless amorphous soloid. [α]D
20
 -165 (c 0.10 MeOH); HR-ESI-MS 
[M+Na]
+
 m/z 667.2742 (calcd. for C34H44O12Na 667.2730, Δ +1.2 mmu); UV λmax 
(MeOH) nm (log ε) 336.5 (1.9), 342.0 (1.7), 275.5 (3.1), and 203.5 (3.9); IR (ATR) νmax 
3489, 2961, and 1743 cm
-1
; 
1
H and 
13
C NMR see Table 5.1. 
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